0000908259 2026-01-01 2026-06-30 0000908259 2026-08-13 0000908259 2026-06-30 0000908259 2025-12-31 0000908259 us-gaap:RelatedPartyMember 2026-06-30 0000908259 us-gaap:RelatedPartyMember 2025-12-31 0000908259 us-gaap:NonrelatedPartyMember 2026-06-30 0000908259 us-gaap:NonrelatedPartyMember 2025-12-31 0000908259 2026-04-01 2026-06-30 0000908259 2025-04-01 2025-06-30 0000908259 2025-01-01 2025-06-30 0000908259 us-gaap:PreferredStockMember 2025-12-31 0000908259 us-gaap:CommonStockMember 2025-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000908259 us-gaap:RetainedEarningsMember 2025-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-12-31 0000908259 us-gaap:PreferredStockMember 2026-03-31 0000908259 us-gaap:CommonStockMember 2026-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000908259 us-gaap:RetainedEarningsMember 2026-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2026-03-31 0000908259 2026-03-31 0000908259 us-gaap:PreferredStockMember 2024-12-31 0000908259 us-gaap:CommonStockMember 2024-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000908259 us-gaap:RetainedEarningsMember 2024-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-12-31 0000908259 2024-12-31 0000908259 us-gaap:PreferredStockMember 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-03-31 0000908259 2025-03-31 0000908259 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000908259 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000908259 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0000908259 2026-01-01 2026-03-31 0000908259 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0000908259 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000908259 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0000908259 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000908259 2025-01-01 2025-03-31 0000908259 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000908259 us-gaap:PreferredStockMember 2026-06-30 0000908259 us-gaap:CommonStockMember 2026-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000908259 us-gaap:RetainedEarningsMember 2026-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-06-30 0000908259 us-gaap:PreferredStockMember 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-06-30 0000908259 2025-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-06-30 0000908259 OTLC:DragonOverseasCapitalLimitedMember 2026-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-06-23 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-01-31 0000908259 OTLC:JVMember OTLC:MayTwoThousandAndTwentyTwoAndJulyTwoThousandAndTwentyFiveNoteMember 2026-01-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2025-07-31 0000908259 OTLC:JVMember OTLC:MayTwoThousandAndTwentyTwoNoteMember 2025-07-31 0000908259 OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 OTLC:IndependentContractorAgreementMember 2025-12-31 0000908259 OTLC:IndependentContractorAgreementMember 2025-12-31 2025-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2025-12-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2022-05-31 0000908259 us-gaap:CommonStockMember OTLC:SecuritiesPurchaseAgreementsMember 2026-06-30 0000908259 us-gaap:CommonStockMember OTLC:SecuritiesPurchaseAgreementsMember 2026-06-01 2026-06-30 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2022-01-31 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2020-06-30 0000908259 OTLC:SinceInceptionDateMember 2024-01-01 2024-12-31 0000908259 2025-01-01 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 OTLC:PointRMergerAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:PointRMergerAgreementMember 2026-06-30 0000908259 OTLC:MastHillMember 2026-01-01 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2024-12-31 0000908259 OTLC:LunaiMember 2026-01-01 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-01-01 2026-06-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:PointRMergerMember 2026-01-01 2026-06-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:PointRMergerMember 2025-01-01 2025-12-31 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2026-04-01 2026-06-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2025-04-01 2025-06-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-06-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-06-30 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2026-06-30 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-01-01 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-01-01 2026-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 us-gaap:FairValueInputsLevel1Member OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel2Member OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:JVMember 2025-12-31 0000908259 OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel1Member OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 us-gaap:FairValueInputsLevel2Member OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputEbitdaMultipleMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputEbitdaMultipleMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputWeightedAverageCostOfCapitalMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:TerminalGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:FairValueInputsLevel3Member OTLC:ProductPenetrationRatesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:FairValueInputsLevel3Member OTLC:ProductPenetrationRatesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0000908259 us-gaap:MeasurementInputSharePriceMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember 2026-01-01 2026-06-30 0000908259 us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0000908259 OTLC:MergerAgreementMember 2019-04-30 0000908259 OTLC:MergerAgreementMember 2019-04-01 2019-04-30 0000908259 OTLC:PointRMember OTLC:MergerAgreementMember 2019-11-30 0000908259 OTLC:PointRMember OTLC:MergerAgreementMember 2022-01-01 2024-12-31 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2026-06-30 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2025-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember 2026-06-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember 2025-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember 2026-06-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember 2025-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember 2026-06-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember 2025-12-31 0000908259 OTLC:ConvertibleDebenturesMember 2026-06-30 0000908259 OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableStephenBoeschMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableStephenBoeschMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableRelatedPartyMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableRelatedPartyMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteBridgeInvestorsMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteBridgeInvestorsMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:MarchTwentyTwentyTwoNotesMember OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:MarchTwentyTwentyTwoNotesMember OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:DebtClinicalTrialsGMPMember OTLC:TwoPercentageConvertibleNotesForeverProsperityMember 2026-06-30 0000908259 OTLC:DebtClinicalTrialsGMPMember OTLC:TwoPercentageConvertibleNotesForeverProsperityMember 2025-12-31 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:AccruedAndUnpaidInterestMember 2026-06-30 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:AccruedAndUnpaidInterestMember 2025-12-31 0000908259 OTLC:JulyTwoThousandTwentyFiveNoteMember OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:JulyTwoThousandTwentyFiveNoteMember OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:JanuaryTwoThousandTwentySixNoteMember OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:JanuaryTwoThousandTwentySixNoteMember OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:PacificPierTwoThousandTwentySixNoteMember OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:PacificPierTwoThousandTwentySixNoteMember OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtBridgeInvestorsMember 2026-06-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtBridgeInvestorsMember 2025-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCFOMember 2026-06-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCFOMember 2025-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAutotelicIncRelatedPartyMember 2026-06-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAutotelicIncRelatedPartyMember 2025-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCEOMember 2026-06-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCEOMember 2025-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAccreditedInvestorMember 2026-06-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAccreditedInvestorMember 2025-12-31 0000908259 OTLC:JHDarbiePPM3DebtMember OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:JHDarbiePPM3DebtMember OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2026-06-30 0000908259 OTLC:BridgeInvestorMember 2026-06-30 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-01 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 2019-12-31 0000908259 OTLC:DrSanjayJhaMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:ChulhoParkMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:AmitShahMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:TwoAccreditedInvestorsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2026-04-01 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2026-01-01 2026-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2025-04-01 2025-06-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2025-01-01 2025-06-30 0000908259 OTLC:GMPNoteMember 2020-06-30 0000908259 OTLC:GMPNoteTwoMember 2021-09-30 0000908259 OTLC:ConvertiblePromissoryNoteMember OTLC:OctoberPurchaseAgreementMember 2021-10-31 0000908259 OTLC:ConvertiblePromissoryNoteMember OTLC:JanuaryPurchaseAgreementMember 2022-01-31 0000908259 OTLC:UnsecuredConvertibleNotePurchaseAgreementsMember 2021-10-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-06-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-12-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-04-01 2026-06-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-01-01 2026-06-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-04-01 2025-06-30 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-31 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-01 2021-08-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-04-01 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-01-01 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-04-01 2025-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-01-01 2025-06-30 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2022-03-31 0000908259 OTLC:FiveInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2022-03-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2023-12-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2026-04-01 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2026-03-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2026-06-30 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2026-01-01 2026-06-30 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000908259 OTLC:BlueLakeMember OTLC:SecuritiesPurchaseAgreementMember 2025-12-31 0000908259 OTLC:BlueLakeMember OTLC:SecuritiesPurchaseAgreementMember 2026-04-01 2026-04-30 0000908259 OTLC:FourthManConvertibleNoteMember 2026-04-01 2026-06-30 0000908259 OTLC:FourthManConvertibleNoteMember 2026-01-01 2026-06-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-04-01 2025-06-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-01-01 2025-06-30 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-31 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-01 2022-05-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastNoteMember 2025-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2026-06-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2026-06-01 2026-06-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:SecuritiesPurchaseAgreementMember 2025-07-31 0000908259 us-gaap:WarrantMember 2025-07-31 0000908259 2025-07-31 2025-07-31 0000908259 OTLC:JVMember OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember 2025-07-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2026-04-01 2026-06-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2026-01-01 2026-06-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2025-01-01 2025-12-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember OTLC:SecuritiesPurchaseAgreementMember 2026-01-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember OTLC:SecuritiesPurchaseAgreementMember 2026-01-23 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember us-gaap:WarrantMember 2026-01-31 0000908259 2026-01-01 2026-01-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember 2026-04-01 2026-06-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember 2026-01-01 2026-06-30 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember 2026-06-23 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember OTLC:SecuritiesPurchaseAgreementMember 2026-06-23 0000908259 2026-06-23 2026-06-23 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember 2026-04-01 2026-06-30 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember 2026-01-01 2026-06-30 0000908259 OTLC:AutotelicMember 2025-01-01 2025-01-01 0000908259 OTLC:AutotelicMember 2025-12-31 0000908259 OTLC:AutotelicMember 2026-06-30 0000908259 OTLC:AutotelicMember 2026-01-01 2026-06-30 0000908259 OTLC:CFOMember 2025-01-01 2025-01-01 0000908259 OTLC:CFOMember 2025-01-01 2025-12-31 0000908259 OTLC:CFOMember 2026-01-01 2026-06-30 0000908259 srt:ChiefExecutiveOfficerMember 2023-12-01 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2025-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-06-30 0000908259 OTLC:BridgeInvestorMember 2026-01-01 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAccreditedInvestorsMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAccreditedInvestorsMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:AugustTwoThousandAndTwentyOneMember 2026-06-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:AugustTwoThousandAndTwentyOneMember 2025-12-31 0000908259 OTLC:FourthManLLCMember OTLC:MarchTwentyTwentyTwoNotesMember 2026-06-30 0000908259 OTLC:FourthManLLCMember OTLC:MarchTwentyTwentyTwoNotesMember 2025-12-31 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MayTwoThousandAndTwentyTwoMember OTLC:MastHillMember 2026-06-30 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MayTwoThousandAndTwentyTwoMember OTLC:MastHillMember 2025-12-31 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MayTwoThousandAndTwentyTwoMember 2026-06-30 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MayTwoThousandAndTwentyTwoMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2026-06-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember 2026-06-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember 2025-12-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember OTLC:TenPercentCouponJanuaryTwoThousandTwentySevenMember 2026-06-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember OTLC:TenPercentCouponJanuaryTwoThousandTwentySevenMember 2025-12-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember 2026-06-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastNoteMember 2025-12-31 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2026-06-30 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2025-12-31 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember 2026-06-30 0000908259 OTLC:JuneTwentyTwentySixFinancingtNoteMember 2025-12-31 0000908259 srt:ChiefFinancialOfficerMember OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 srt:ChiefFinancialOfficerMember OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 OTLC:BridgeInvestorMember OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:AutotelicMember OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 OTLC:AutotelicMember OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:ChiefExecutiveOfficerRelatedPartyMember OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 OTLC:ChiefExecutiveOfficerRelatedPartyMember OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:AccreditedInvestorMember OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 OTLC:AccreditedInvestorMember OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember 2026-06-30 0000908259 OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:JVMember 2026-06-30 0000908259 OTLC:JVMember 2026-06-30 0000908259 OTLC:GMPBioMember 2026-06-30 0000908259 OTLC:DragonOverseasMember 2026-06-30 0000908259 OTLC:GoldenMountainPartnersMember 2026-06-30 0000908259 OTLC:JVMember 2026-01-01 2026-06-30 0000908259 OTLC:JVMember 2025-01-01 2025-06-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 OTLC:AccreditedInvestorsMember us-gaap:WarrantMember 2024-01-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementTwoMember 2023-07-01 2024-01-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember 2024-01-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:NewSubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:NewSubscriptionAgreementsMember 2025-12-31 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:NewSubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-12-31 0000908259 us-gaap:CommonStockMember OTLC:JHDarbiePlacementAgreementTwoMember 2025-12-31 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-01-01 2026-06-30 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2025-01-01 2025-06-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2026-01-01 2026-06-30 0000908259 OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsTwoMember 2026-06-30 0000908259 OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsTwoMember 2025-12-31 0000908259 OTLC:SubscriptionAgreementsTwoMember 2026-06-30 0000908259 OTLC:SubscriptionAgreementsTwoMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-06-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-06-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-06-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-06-30 0000908259 us-gaap:MeasurementInputExpectedTermMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbieSubscriptionAgreementMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbieSubscriptionAgreementMember 2025-12-01 2025-12-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbieSubscriptionAgreementMember 2025-12-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbieSubscriptionAgreementMember 2025-12-01 2025-12-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbieSubscriptionAgreementMember 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:SubscriptionAgreementsMember 2025-12-31 0000908259 srt:MinimumMember OTLC:JHDarbieSubscriptionAgreementMember 2024-05-01 2024-05-31 0000908259 srt:MaximumMember OTLC:JHDarbieSubscriptionAgreementMember 2024-05-01 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2024-05-01 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:AccreditedInvestorsMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:NewSubscriptionAgreementsMember 2026-01-01 2026-06-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbieSubscriptionAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-01-01 2025-12-31 0000908259 us-gaap:CommonStockMember OTLC:JHDarbieSubscriptionAgreementMember 2026-06-30 0000908259 us-gaap:CommonStockMember OTLC:JHDarbieSubscriptionAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-01-01 2025-06-30 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbieSubscriptionAgreementMember 2026-04-01 2026-06-30 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbieSubscriptionAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:JHDarbiePPMThreeDebtMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsMember 2026-06-30 0000908259 OTLC:JHDarbiePPMThreeDebtMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:SubscriptionAgreementsTwoMember 2026-06-30 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:SubscriptionAgreementsTwoMember 2025-12-31 0000908259 us-gaap:IntellectualPropertyMember OTLC:ServiceAgreementMember OTLC:LunaiBioworksIncMember 2026-04-17 2026-04-17 0000908259 OTLC:LunaiBioworksIncMember OTLC:MergerAgreementMember 2026-04-26 0000908259 OTLC:LunaiBioworksIncMember OTLC:SeriesBConvertiblePreferredStockMember OTLC:MergerAgreementMember 2026-05-01 0000908259 OTLC:LunaiBioworksIncMember OTLC:SeriesBConvertiblePreferredStockMember OTLC:MergerAgreementMember 2026-05-01 2026-05-01 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember OTLC:MergerAgreementMember 2026-05-01 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember OTLC:MergerAgreementMember 2026-05-01 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember OTLC:MergerAgreementMember 2026-05-01 2026-05-01 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember OTLC:AssetTransferAgreementMember 2026-04-30 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2026-04-01 2026-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2025-04-01 2025-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2026-01-01 2026-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2025-01-01 2025-06-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:VuongTrieuMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-30 0000908259 OTLC:VuongTrieuMember OTLC:FallTwoThousandAndNineteenNoteMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember 2025-01-01 0000908259 OTLC:VuongTrieuMember 2025-12-31 0000908259 OTLC:VuongTrieuMember 2026-06-30 0000908259 srt:MaximumMember OTLC:VuongTrieuMember OTLC:SeriesAConvertiblePreferredStockMember 2025-11-01 2025-11-30 0000908259 OTLC:VuongTrieuMember us-gaap:CommonStockMember 2025-11-01 2025-11-30 0000908259 srt:MaximumMember OTLC:VuongTrieuMember OTLC:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-01-31 0000908259 OTLC:VuongTrieuMember us-gaap:CommonStockMember 2026-01-01 2026-01-31 0000908259 OTLC:DrVuongTrieuMember 2025-12-31 0000908259 OTLC:DrVuongTrieuMember 2026-06-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2025-01-01 0000908259 OTLC:AutotelicIncMember 2025-12-31 0000908259 OTLC:AutotelicIncMember 2026-06-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2026-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2026-04-01 2026-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2026-01-01 2026-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2025-04-01 2025-06-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2025-01-01 2025-06-30 0000908259 OTLC:StevenKingMember OTLC:TermSheetAgreementMember 2024-04-01 2024-04-30 0000908259 us-gaap:WarrantMember OTLC:EquityPurchaseAgreementMember 2025-08-31 0000908259 us-gaap:CommonStockMember OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 OTLC:EquityPurchaseAgreementMember 2025-08-31 0000908259 2026-04-01 2026-04-30 0000908259 2026-05-01 2026-05-31 0000908259 2026-05-31 0000908259 2026-06-01 2026-06-30 0000908259 OTLC:PacificPierMember 2026-06-01 2026-06-30 0000908259 OTLC:FourthManLLCMember 2025-03-01 2025-03-31 0000908259 OTLC:SeriesAConvertiblePreferredStockMember 2026-06-30 0000908259 srt:MaximumMember OTLC:VuongTrieuMember OTLC:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:RestrictedStockAwardsMember 2026-01-01 2026-06-30 0000908259 OTLC:DrVuongTrieuMember OTLC:RestrictedStockAwardsMember 2026-04-01 2026-06-30 0000908259 OTLC:DrVuongTrieuMember OTLC:RestrictedStockAwardsMember 2025-01-01 2025-12-31 0000908259 OTLC:DrVuongTrieuMember 2026-04-01 2026-06-30 0000908259 OTLC:DrVuongTrieuMember 2026-01-01 2026-06-30 0000908259 us-gaap:PreferredStockMember 2026-01-01 2026-06-30 0000908259 us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0000908259 OTLC:JeffersonCapitalMember 2025-08-01 2025-08-31 0000908259 OTLC:JeffersonCapitalMember 2026-04-01 2026-06-30 0000908259 OTLC:JeffersonCapitalMember 2026-01-01 2026-06-30 0000908259 OTLC:JeffersonCapitalMember 2026-06-30 0000908259 OTLC:JeffersonCapitalMember 2025-01-01 2025-12-31 0000908259 OTLC:JeffersonCapitalMember 2025-12-31 0000908259 OTLC:ValorNationMember 2025-08-01 2025-08-31 0000908259 OTLC:ValorNationMember 2025-01-01 2025-12-31 0000908259 OTLC:BoxCapitalIncMember 2025-12-01 2025-12-31 0000908259 OTLC:BoxCapitalIncMember 2026-01-01 2026-06-30 0000908259 OTLC:BoxCapitalIncMember 2026-04-01 2026-06-30 0000908259 OTLC:BoxCapitalIncMember 2025-01-01 2025-12-31 0000908259 srt:MaximumMember OTLC:TwoThousandSeventeenEquityIncentivePlanMember 2026-06-30 0000908259 OTLC:TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember 2026-06-30 0000908259 OTLC:ExercisePriceOneMember 2026-01-01 2026-06-30 0000908259 OTLC:ExercisePriceOneMember 2026-06-30 0000908259 OTLC:ExercisePriceTwoMember 2026-01-01 2026-06-30 0000908259 OTLC:ExercisePriceTwoMember 2026-06-30 0000908259 OTLC:ExercisePriceThreeMember 2026-01-01 2026-06-30 0000908259 OTLC:ExercisePriceThreeMember 2026-06-30 0000908259 OTLC:ExercisePriceOneMember us-gaap:WarrantMember 2026-06-30 0000908259 OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2026-06-30 0000908259 srt:MinimumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2026-06-30 0000908259 srt:MaximumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2026-06-30 0000908259 OTLC:ExercisePriceThreeMember us-gaap:WarrantMember 2026-06-30 0000908259 OTLC:ExercisePriceFourMember us-gaap:WarrantMember 2026-06-30 0000908259 OTLC:ExercisePriceFiveMember us-gaap:WarrantMember 2026-06-30 0000908259 OTLC:PointRMergerMember OTLC:MergerAgreementMember 2026-01-01 2026-06-30 0000908259 OTLC:PointRMergerMember OTLC:MergerAgreementMember 2026-06-30 0000908259 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 us-gaap:SubsequentEventMember 2026-08-03 2026-08-03 0000908259 us-gaap:SubsequentEventMember OTLC:SpecialPurchaseAgreementsMember 2026-08-03 0000908259 OTLC:VuongTrieuPhDMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 OTLC:AnthonyEMaidaIIIPhDMAMBAMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 OTLC:StevenWKingMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 OTLC:SeymourFeinMDMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 OTLC:SaranSaundMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 0000908259 OTLC:AmitShahMember us-gaap:SubsequentEventMember 2026-07-10 2026-07-10 iso4217:USD shares iso4217:USD shares pure false Q2 --12-31 0000908259

10-Q true 2026-06-30 2026 false 000-21990 Oncotelic Therapeutics, Inc. DE 13-3679168 29397 Agoura Road Suite 107 Agoura Hills CA 91301 (650) 635-7000 Common Stock OTLC Yes Yes Non-accelerated Filer true false false 457512796

186014

88857

20000

2058

51324

1252670

1038071

1460742

1198252

1101760

2788230

1400000

388000000

394750732

393088242

2554999

2571123

349138

348111

2625000

337256

350044

7925881

8225669

4114684

4023331

4114684

4023331

17906958

18143278

1854395

1663405

111550000

131311353

131356683

0.01

15000000

50900

24388

509

244

0.01

750000000

457012796

442596856

4570125

4425968

50556882

47095219

209433535

211239164

264561051

262760595

-1121672

-1029036

263439379

261731559

394750732

393088242

250000

345

297

1140

594

1093220

65672

2945810

166472

1093565

65969

2946950

167066

-843565

-65969

-2696950

-167066

1100000 1100000

300000

318292

207780

614103

411579

102868

484198

12788

424830

1184576

276418

798685

13251

341011

210449

-1898265

-153815

-47136

-67407

-92636

-132955

388147

277856

-1805629

-20860

0.00

-0.00

447386505

408292720

445596158

407860290

0.00

-0.00

467914165

452809058

445596158

407860290

24388

244

442596856

4425968

47095219

211239164

-1029036

261731559

26512

265

2588227

2588492

1600446

16002

114764

130766

-2193776

-45500

-2239276

50900

509

444197302

4441970

49798210

209045388

-1074536

262211541

11877507

118775

728695

847470

800000

8000

24727

32727

137987 1380 5250 6630

388147

-47136

341011

50900

509

457012796

4570125

50556882

209433535

-1121672

263439379

407289888

4072899

42219400

-38040668

-774119

7477512

1002832

10028

60170

70198

-298716

-65548

-364264

408292720

4082927

42279570

-38339384

-839667

7183446

277856

-67407

210449

408292720

4082927

42279570

-38061528

-907074

7393895

-1898265

-153815

302014

81095

2372257

1100000

300000

130766

12788

424830

-49266

214599

1487

235882

204904

1027

-434440

-293106

6630

500000

57922

295000

32955

531597

295000

97157

1894

108857

106128

206014

108022

163597

175650

163495 847470 70198 1100000

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) was originally incorporated in the State of New York in 1988 as OXiGENE, Inc. The Company reincorporated in the State of Delaware in 1992, changed its name to Mateon Therapeutics, Inc. (“Mateon”) in 2016, and subsequently changed its name to Oncotelic Therapeutics, Inc. in November 2020. The Company conducts business through Oncotelic and its wholly owned subsidiaries, including Oncotelic, Inc., PointR Data, Inc. (“PointR”), Pet2DAO, Inc. (“Pet2DAO”), and EdgePoint AI, Inc. (“EdgePoint”), a consolidated subsidiary with non-controlling interests. (Collectively, “Oncotelic,” “we,” “our,” or “the Company”). Further detail on prior mergers and corporate history is provided in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2026. The Company is principally focused on the development of immuno-oncology therapeutics, including OT-101, a transforming growth factor-beta (“TGF-β”) inhibitor being advanced for difficult-to-treat cancers and viral respiratory diseases. OT-101 is being developed through our joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), affiliates of Golden Mountain Partners (“GMP”). The Company entered into a JV with Dragon to form GMP Bio in March 2022. The Company’s ownership interest in GMP Bio is <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zaVKCGycxyD1" title="Ownership interest">45%, while that of Dragon is <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonOverseasCapitalLimitedMember_zii5t7gECVej" title="Ownership interest">55%. GMP Bio and the Company will focus to further expand the development of OT-101 for various oncology indications like pancreatic cancer, melanomas, gliomas etc. as also for viral infections like COVID-19. This path is being evaluated as a monotherapy, as well as combination therapies in conjunction with other drugs like checkpoint inhibitors. The JV is also developing five other nanoparticles for various cancer therapies. The pharmaceutical development of OT-101, our nano-particle platform and other artificial intelligence (“AI”) development is being advanced through our JV. In addition, the JV has also set up a FDA certified cGMP development and manufacturing facility in San Diego, California which is capable of drug development and manufacture of Phase 1 clinical trial materials. During the year ended December 31, 2025, GMP Bio completed an independent third-party valuation by an offshore independent valuation firm, which preliminarily estimated the potential value of the drug pipeline under development at approximately $2.3 billion. This valuation was non-binding, forward-looking, and based upon a number of assumptions including the successful achievement of clinical, regulatory, and commercial milestones. That valuation was interpreted not to be a current measure of fair value under the United States Generally Accepted Accounting Principles (“U.S. GAAP”). Oncotelic conducted an assessment of the change in fair value and hired the services of a separate, ASC-compliant valuation firm to perform a valuation of GMP Bio under U.S. GAAP standards. The results of this valuation that indicated a change in the value of the Company’s holdings in GMP Bio have been incorporated into this, consistent with the Company’s fair value reporting under U.S. GAAP. The valuation conducted by the independent valuation firm conducted a fair value of GMP Bio based on various methods compliant with US GAAP to derive the fair value. The Company then utilized the fair value of GMP Bio as assessed by the valuation firm, attributed the ownership of the Company in GMP Bio to ascertain the Company’s interest in GMP Bio, and recorded the resulting gain to the investment in GMP Bio at fair value. The Company relied on the inputs by the JV valuation, however, certain parameters like lack of marketability, lack of control discounts and other standard discounts, specific to the Company, have been applied to the independent valuation done by the Company to derive the ASC-compliant valuation. As the circumstances related to the JV have not materially changed since December 31, 2025 till the date of this filing, the Company qualitatively assessed and determined that no additional fair value adjustment was required and hence, the Company has not recorded a change in value of the Company’s interest in the JV. In the future, the Company will appropriately adjust the fair value of the Company’s interest in the JV, at the end of reporting periods, and when key value inflection points are met or the Company observes conditions that require the fair value of the Company’s interest in the JV to be adjusted. The JV continues preparing for planned Phase 2 and Phase 3 trials for OT-101 in high-grade glioma, pancreatic cancer, and other indications. The JV is also sponsoring investigator-initiated clinical studies in additional oncology applications. In addition, the JV is developing five additional therapeutic candidates, which, if successfully developed and approved, are anticipated to contribute significant revenues, income and meaningful long-term value to both the JV and the Company. In addition to the development of OT-101 (also referred to as Sapu-002), the JV is advancing the development of five additional therapies: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sapu-001 – A paclitaxel-based taxane therapy, which can address cancers like breast cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sapu-003 – An evorolimus formulation, which can address renal cell cancer, neuroendocrine tumors and tuberous sclerosis complex (renal angiomyolipoma and subependymal giant cell astrocytoma)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sapu-004 – A carboplatin formulation, which can address small cell lung cancer, head and neck cancer and testicular cancer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sapu-005 – A palbociclib formulation, which would address HR+, HER2- breast cancer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">e.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sapu-006 – A docetaxel formulation, which can address prostate cancer and gastric cancer.</td></tr> </table> Each of these therapies, and the various cancers they address, have shown they are increasing in terms of incidences and that opens up the avenue to be able to generate revenues ranging from several millions of dollars to several hundreds of millions of dollars, if successfully developed and commercialized. Although no assurances can be given, GMP Bio currently intends to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the unaudited Notes to the Condensed Consolidated Financial Statements. The Company’s core scientific focus is the development of its proprietary self-immunization protocol (“SIP™”), designed to stimulate a patient’s immune system to recognize and target tumors without requiring tumor extraction or antigen identification. The SIP™ platform is supported by more than three decades of RNA-based research and is being applied initially to oncology, with potential expansion to Duchenne Muscular Dystrophy (“DMD”) and other diseases driven by TGF-β overexpression. Separately from the JV, the Company plans to develop OT-101 for select animal-health indications and is evaluating the use of digital assets and blockchain-based technologies to support that platform. The Company acquired apomorphine for potential uses in Parkinson’s disease, erectile dysfunction, and female sexual dysfunction. The Company continues to evaluate advancement opportunities for OXi4503 (for acute myeloid leukemia and myelodysplastic syndromes) and CA4P (in combination with checkpoint inhibitors for metastatic melanoma). The development of all these products will be subject to the availability of resources to develop them. In April 2026, the Company announced that it had entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform. This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise. The system under development is designed to operate within GMP-regulated environments and is intended to enable automated material handling, real-time monitoring, and PDAOAI-enhanced compliance workflows across pharmaceutical manufacturing and related applications. For more information on the partnership with TechForce, refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026. Agreement and Plan of Merger with Lunai Bioworks Inc. In April 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc. (“Lunai”), a Delaware corporation, Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”). In connection with the Merger Agreement, the Company entered into an IP Assignment Agreement with Holdings, pursuant to which it agreed to contribute and assign certain assets relating to the intellectual property of the Company (collectively, the “Intellectual Property Assets”) to Holdings. For more discussion on the transactions with Lunai, refer to Note 9 of these Notes to Condensed Consolidated Financial Statements. Fundraising Pacific Pier June 2026 Note On June 23, 2026, the Company entered into a Securities Purchase Agreement (the “2026 Pacific Pier SPA”), with Pacific Pier Capital II, LP (“Pacific Pier”), pursuant to which Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “2026 Pacific Pier Note”). The 2026 Pacific Pier Note is convertible into shares of the Company’s common stock par value $0.01 per share (“Common Stock”). For more information on the Pacific Pier financing of the Company, refer to Note 5 of the Notes to the Condensed Consolidated Financial Statements. Mast Hill January 2026 Note In January 2026, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $398,333 that is convertible into shares of the Company’s Common Stock. Proceeds from this note are to be utilized for corporate expenses. This note, the May 2022 Note and the July 2025 Note are securitized against all the assets of the Company, excluding the <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20260131__srt--TitleOfIndividualAxis__custom--MayTwoThousandAndTwentyTwoAndJulyTwoThousandAndTwentyFiveNoteMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JVMember_zeYbWgfzoZf5" title="Ownership interest">45% ownership of the Company in the JV. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements. Mast Hill July 2025 Note In July 2025, the Company entered into a Securities Purchase Agreement with Mast Hill, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of approximately $0.6 million, which is convertible into shares of the Company’s Common Stock. This note was utilized for corporate expenses. This note, and the May 2022 Note were securitized against all the assets of the Company, excluding the <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250731__srt--TitleOfIndividualAxis__custom--MayTwoThousandAndTwentyTwoNoteMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JVMember_zwpOcXvusoig" title="Ownership interest">45% ownership of the Company in the JV. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements. Mast Hill Equity Purchase Agreement In August, 2025, the Company entered into an Equity Purchase Agreement (the “Mast EPA”) and a Registration Rights Agreement (the “Mast Registration Rights Agreement”) with Mast, pursuant to which the Company shall have the right, but not the obligation, to direct Mast, to purchase up to $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn6n6_c20250801__20250831__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_z7pXig9MSc6j" title="Maximum commitment amount">25 million (the “Maximum Commitment Amount”) in shares of the Company’s Common Stock in multiple tranches. The Company instructed Mast Hill in June 2026 to purchase approximately 138,000 shares of Common Stock for cash proceeds of approximately $6,600 and incurred a cost of approximately $1,500 against the sale of the Common Stock. The Company plans to file a post-effective amendment to the registration statement with the SEC at the earliest. For more information on the Mast EPA, refer to Note 10 of the Notes to the unaudited Condensed Consolidated Financial Statements. Jefferson Capital Ventures, LLC and Valor Nation, Inc Independent Contractor Agreements In August 2025, the Company entered into independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) and Valor Nation, Inc. (“Valor”) for providing certain consulting and advisory services. The ICAs call for Jefferson and Valor to provide consulting and advisory services including strategic planning meetings, coordination non-legal support for SEC compliance, balance sheet and income statement optimization strategies, shareholder and investor communication planning, liaison with investment bankers, analysts, and institutional investors, operational efficiency and cost-saving recommendations and ancillary strategic services not requiring a license, corporate planning, operations and capital markets advisory services not requiring licenses. For more information on the Jefferson and Valor ICAs, refer to our Current Report on Form 8-K filed with the SEC on August 12, 2025. Further on December 31, 2025 the Company reported modifying the threshold of the first milestone contained within the ICA with Jefferson, to earn certain RSAs of shares the Company’s Common Stock upon the achievement of certain corporate milestones. The amendment modified the Company’s market capitalization exceeded $100 million requirement on any single trading day’s close to $45 million on any single trading day’s close. This amendment was to enable the Company to be able to continue to build on its progress to date including making effective it’s equity line with Mast Hills, engagement of AGP for future financing, and engaging Sichenzia, Ross and Ferrell (“SRF”) for uplisting the Corporation’s stock to a nationally recognized stock exchange and to achieve its corporate goals contained within the said ICA. For more information on the modification, refer to our Current Report on Form 8-K filed with the SEC on January 6, 2026. In connection with the engagement with SRF, the Company filed an initial application with Nasdaq on July 28, 2026. Private Placement 3 & JH Darbie Financing In December 2025, the Company completed the conversion of the debt of forty-seven (47) accredited investors from the JH Darbie Financing from our prior private placement (“PPM-2”) into the new subscription agreements under the new financing (“PPM-3”) in three tranches, which resulted in conversion of approximately $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z7VrrPBozDT6" title="Debt conversion amount">2.2 million. JH Darbie and the Company are parties to a May 2024 placement agent agreement (“Placement Agreement”), pursuant to which <span id="xdx_90D_eus-gaap--DebtConversionDescription_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zKSibflpvBD1" title="Debt conversion, description">JH Darbie had the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Two of the investors did not participate in PPM-3 and their 7 units for a total of approximately $0.2 million were converted into short term loan to the Company, of which one investor was paid off during the six months ended June 30, 2026. For more information on the PPM-3 Financing, refer to Note 8 of these Notes to the Condensed Consolidated Financial Statements. May 2022 Note In May 2022, the Company entered into a Securities Purchase Agreement with Mast Hill, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of approximately $0.7 million, which note is convertible into shares of the Company’s Common Stock. The May 2022 Note was extended till December 2026. In June 2026, Mast Hill converted the balance of the May 2022 Note, including accrued interest and penalty, of approximately $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTEOHFPaxWQ8" title="Debt instrument, face amount">847,000 into approximately <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn5n6_c20260601__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zzPj8FlgTI32" title="Conversion fee, shares">11.9 million shares of the Company’s Common Stock. As of June 30, 2026, this note is fully converted. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements. Forever Prosperity (previously GMP) Note purchase agreements and unsecured notes Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20220131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndPurchaseAgreementMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersMember_zzzbnp4adDR8" title="Debt instrument face amount"><span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndPurchaseAgreementMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersMember_zlfZcpZvdzpk" title="Debt instrument face amount">4.5 million. Such notes were assigned to Forever Prosperity, LLC, an affiliated entity of GMP. For more information on the GMP debt financing, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements. Mosaic ImmunoEngineering, Inc. Term Sheet In April 2024, the Company entered into a binding term sheet (the “Term Sheet”) with Mosaic Immuno Engineering, Inc. (“Mosaic”). For more information on the Term Sheet, refer to the Current Report on Form 8-K filed with the SEC on April 29, 2024. In August 2024, Mosaic and the Company mutually agreed to extend the date of the Term Sheet to expire at the earlier of (1) the signing of definitive agreements or (2) December 31, 2024. In December 2024, the Company and Mosaic further extended the term of the term-sheet to expire at the earlier of (1) the signing of definitive agreements or (2) June 30, 2025. Both Mosaic and the Company are in discussions as to the future of this Term Sheet and how to proceed on this front. Joint Development, Manufacturing and Licensing Agreement with TechForce Robotics In March 2026, the Company entered into a Joint Development, Manufacturing, and Licensing Agreement (the “TechForce Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation. The TechForce Agreement establishes a framework for the joint development, and manufacturing of AI-enabled, GMP-compliant robotic systems for use in pharmaceutical and related manufacturing environments. The integrated product to be developed (the “Product”) combines TechForce’s robotic hardware with the Company’s proprietary PDAOAI Platform. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Oncotelic, its wholly owned subsidiaries, Oncotelic Inc. PointR, and EdgePoint our consolidated non-controlled interest entity. Intercompany accounts and transactions have been eliminated in consolidation. The Company’s investment in GMP Bio is recorded and reported as a minority investment in equity securities. The Company also holds an equity investment in Lunai. The Company has determined that it does not have a controlling financial interest in Lunai and does not exercise significant influence over its operating or financial policies. Accordingly, the investment is not consolidated and is not accounted for under the equity method. The investment is accounted for in accordance with the applicable guidance for equity securities in ASC 321 and is included in “Investment in equity securities” in the accompanying unaudited condensed consolidated balance sheet. Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements as of June 30, 2026 and for the three and six months ended June 30, 2026, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-Q and Article 8 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on April 15, 2026. In management’s opinion, all normal, and recurring adjustments necessary for a fair statement, have been included. The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results for the year ending December 31, 2026. Liquidity and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Prior to December 31, 2024, the Company incurred net losses of approximately $38.0 million. During the year ended December 31, 2025, the Company recorded a net profit of approximately $249.3 million, primarily due to an increase in fair value of the Company’s ownership in GMP Bio of approximately $<span id="xdx_902_eus-gaap--IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1_pn5n6_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zritZLqPMnrd" title="Increase in fair value ownership">365.4 million, reduced by deferred taxes of approximately $111.6 million. During the six months ended June 30, 2026, the Company incurred a loss of approximately $1.9 million. The Company has a negative working capital of approximately $16.4 million at June 30, 2026, of which approximately $2.6 million contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company has negative cash flows from operations for the six months ended June 30, 2026 of approximately $0.4 million. In the past few years, barring the funding raised during the six months ended June 30, 2026 through Mast Hill and Pacific Pier, and short-term funding from related parties, the Company has not been able to raise any substantial funding during the past few years from other third parties. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur lower costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the need to raise capital to remain viable. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company’s long-term plans include continued development of its current pipeline of products, in addition to continue the development of OT-101 which is exclusively out-licensed to the JV and the JV will be responsible for the funding required to support the development in entirety, to generate sufficient revenues, through either technology transfer or product sales, or raise additional financing to cover its anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. During the six months ended June 30, 2026, the Company raised an aggregate amount of $0.5 million from the issuance of convertible debt instruments. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for twelve months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations or cease operations completely.

0.45

0.55

2300000000

178410

0.01

398333

0.45

600000

0.45

25000000

138000

6600

1500

100000000

45000000

2200000

JH Darbie had the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Two of the investors did not participate in PPM-3 and their 7 units for a total of approximately $0.2 million were converted into short term loan to the Company, of which one investor was paid off during the six months ended June 30, 2026. For more information on the PPM-3 Financing, refer to Note 8 of these Notes to the Condensed Consolidated Financial Statements.

700000

847000

11900000

4500000

38000000.0

249300000

365400000

111600000

1900000

-16400000 2600000

-400000

500000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and related valuation allowance, and fair value of financial instruments. Cash and Restricted Cash As of June 30, 2026, and December 31, 2025, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2026, and December 31, 2025. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes. Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring. Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets or liabilities at June 30, 2026 and December 31, 2025. Investment in equity securities The Company holds equity investments in GMP Bio and Lunai Bioworks Inc. that do not result in a controlling financial interest or significant influence. The Company has elected the fair value option under ASC 825, Financial Instruments. Consequently, these investment are carried at fair value on the unaudited Condensed Consolidated Balance Sheets, with all subsequent changes in fair value recognized immediately in earnings under ASC 321. Unrealized gains and losses resulting from changes in fair value are reported within other income (expense), net on the unaudited Condensed Consolidated Statements of Operations. Below is the change in the fair value of the Company’s equity investments for the six months ended June 30, 2026 and the Audited Consolidated Statements of Operations for the year ended December 31, 2025: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Investment in GMP Bio (JV)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zubIVfEvBCVc" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zl7eWKqfuUqa" style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_z5Equ1s1ZCj8" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Investment Lunai</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zvoFQeoz9God" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, initial book value">1,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zsbtUiqHzQL3" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, unrealized gains">300,000</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zwaCwv3xjDg9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, fair value">1,400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630_zd86mSgKgQKi" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">389,100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630_zPkeim4GxsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">300,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630_zJ5MlgdcJom5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">389,400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (JV)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zsqLcwXhtSgi" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zDvYXnlmzvCg" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">365,346,775</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zJlZNOFyBfLj" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">388,000,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231_zn5UJ541cM4f" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231_zVCBfOqqg29f" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">365,346,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231_zzaXBKRT9FC5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of June 30, 2026 and December 31, 2025. During the year ended December 31, 2025, there was a change in the long-term value of the Company’s investment in equity securities of GMP Bio and as such has been recorded as above. No similar change in fair value has been recorded in the long-term value of the GMP Bio investment during the six months ended June 30, 2026 as the Company has not observed any qualitative conditions required to record any further changes to the fair value. For more information, see Change in Fair Value of Equity Securities of GMP Bio below. In addition, the Company recorded a $1.1 million initial non-cash gain in exchange for a non-financial asset and a $0.3 million gain from the change in the fair value of the Company’s equity securities in Lunai received during the three and six months ended June 30, 2026. No similar gains were recorded during the comparable periods in prior year. For more information, see Note 9 – Lunai Bioworks Transactions below. Change in Fair Value of Equity Securities of GMP Bio On March 31, 2022, the Company entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the Company received a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zqaCiahQA495" title="Ownership percentage">45% ownership interest in the JV. The combined enterprise value of GMP Bio, on the date of the formation of the JV, was approximately $<span id="xdx_904_ecustom--JointVentureCombinedEnterpriseValue_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zNbHt4hQAHWb" title="Joint venture combined enterprise value">50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $<span id="xdx_90B_eus-gaap--JointVentureFormationFairValueOfJointVenture_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z9TyFifMCT8f" title="Fair value of investment in joint venture">22.7 million and the total original capital contributions by Dragon Overseas of approximately $<span id="xdx_902_ecustom--JointVentureOtherParticipantCapitalContribution_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zJ27wDFdbL6j" title="Joint venture other participant capital contribution">27.7 million. As of December 31, 2024, the carrying value of the Company’s investment in GMP Bio was approximately $<span id="xdx_909_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_iI_pn4n6_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z7cuPEQb97dd" title="Carrying value of investment">22.7 million, which was included in Investment in GMP Bio at fair value on the unaudited condensed consolidated balance sheets. The investment in GMP Bio has been accounted for under the fair value method of accounting. Similarly, during the year ended December 31, 2025, the Company determined that a remeasurement of its investment to fair value was appropriate. All the factors described below allowed the Company to form a basis for a triggering event of significant development for the JV and justified the JV, and consequently the Company, to reassess the fair value of the JV. The JV’s principal activities centered on the commercialization of OT-101 for certain oncology indications in the US and looking at other territories as well. In March 2025, the JV successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, the JV plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The JV is also sponsoring investigator-initiated studies for OT-101 for other oncology indications including lung cancer (non-small cell lung cancer- NSCLC- and Mesothelioma.- MPM) and has started clinical development for OT-101 for pancreatic cancer. Over ten patent families have been filed exploiting the central role of TGFB2 as prognostic indicator for cancer survival and one patent family for the intracranial delivery device of brain cancer with issued patent in China and Germany. In addition to OT-101, the JV has developed a nanoparticle platform (“Nano Platform”) that entails the formulation of products in new nanoparticle sizes. The JV anticipates that the Nano Platform may offer superior platform for the absorption of water insoluble drugs across a broad spectrum of cancers. The JV is working on improved formulations for OT-101 with new nanoparticle sizes. In addition, the JV has identified five additional compounds as product candidates on the Nano Platform, including the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV has completed the formulation development of the first product, everolimus for injection. The JV has initiated a global clinical trial for that product, including open patient enrollment in Australia. The JV hopes to complete the Phase 1 trial and to move to a Phase 3 noninferiority trial against Affinitor. Phase 3 trial is slated to initiate within one year with completion and submission for marketing approval no less than three years thereafter.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV is developing palbociclib for injection on the Nano Platform and expects to file the investigational new drug (“IND”) and to initiate a Phase 1 trial in 2026.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV is developing docetaxel and paclitaxel for injection on the Nano Platform and expects to file the IND to initiate a Phase 1 trial for this product candidate in 2026. These are expected to go through the 505(b)2 bioequivalence pathway which should result in rapid entrance into the market</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition, the JV has also identified developing carboplatin and intends to begin the development as soon as the other products clinical trials are under way</td></tr> </table> The DeciparticleTM platform has proven robust and is being expand to other drug candidates through partnering. The platform is protected by more than 15 patent families covering chemical composition, manufacturing, and method of use. The JV built a GMP manufacturing facility in San Diego, California (the “San Diego Facility”). In late 2024, the San Diego Facility was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. A significant portion of the manufacturing for the Nano Platform, including the development of Phase I clinical trial materials, is conducted at the San Diego Facility. Evaluation of larger commercial scale manufacturing is ongoing. In early 2025, the Company entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid IND development platform to support up to 20 IND projects, including INDs developed by the JV. All six of the compounds that the JV is developing are planned to be initiated under these INDs, and are focused on next-generation anticancer agents. During the year ended December 31, 2025, GMP Bio completed an independent third-party valuation by an offshore independent valuation firm, which preliminarily estimated the potential value of the drug pipeline under development at approximately $<span id="xdx_90E_eus-gaap--DevelopmentCosts_pn8n9_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zxpkUc0omFx7" title="Development costs">2.3 billion. This valuation was a non-binding, forward-looking, and based upon a number of assumptions including the successful achievement of clinical, regulatory, and commercial milestones. That valuation was interpreted not to be a current measure of fair value under U.S. GAAP. Although no assurances can be given, GMP Bio currently intends to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the unaudited Notes to the unaudited Condensed Consolidated Financial Statements. The Company then conducted its own independent assessment of the valuation of the JV. The basis for the valuation was reliance on the valuation report of the third party offshore valuation firm, including the financial projection, risks and parameters of assessment as done by the offshore independent valuation firm, and then applying additional independent parameters, like discounts for lack of marketability and lack of control, and other standard discounts, required to adhere to the ASC-compliant standards as generally used in the United States. The Company hired the services of an independent, ASC-compliant valuation firm to review, perform and validate the assumptions considered by the Company and provide an ASC-compliant valuation of the JV under U.S. GAAP standards. The valuation conducted by the independent ASC-compliant valuation firm of the JV was based on various methods compliant with ASC and U. S. GAAP to derive the fair value. The Company then utilized the fair value of GMP Bio, as assessed by the ASC-compliant valuation firm, attributed the ownership percentage of the Company in GMP Bio, to ascertain the Company’s interest in GMP Bio and recorded the resulting gain to the investment in GMP Bio at fair value. As the circumstances related to the JV have not materially changed since December 31, 2025, the Company assessed and determined that no additional fair value adjustment was required during the six months ended June 30, 2026, and hence, the Company has not recorded a change in value of the Company’s interest in the JV. The Company will appropriately adjust the fair value of the interest of the Company’s interest in the JV at the end of future reporting periods and when key value inflection points are met. As many of the inputs considered for the purpose of the valuation are unobservable inputs including, but not limited to, the potential revenue projections, the probability of success, the conduct of the clinical trials under accelerated timelines of approvals by the territorial regulatory bodies similar to the 505(b)(2) pathway under the US FDA regulations, the timing of completion of the clinical trials and approvals of the products, timing of product launches, estimates for working capital, additional research and development and general and administrative expenses, estimated tax rates, interest rates of potential debt and many others. The fair value of the Company’s investment was determined in accordance with ASC 820 Fair Value Measurement and is classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The valuation was performed with the assistance of an independent third-party valuation specialist and utilized an income approach (discounted cash flow method) and market-based approach (guideline public company multiples) and recent transactions, where available, to corroborate the results of the income approach. The final value was then arrived at by calculating the average of the values under the two approaches. The income approach of valuation incorporates assumptions that market participants would use in pricing the asset, including estimates of future financial performance and the selection of an appropriate discount rate. As the circumstances related to the JV have not materially changed since December 31, 2025, and June 30, 2026, the Company assessed and determined that no additional fair value adjustment was required and hence, the Company has not recorded a change in value of the Company’s interest in the JV. Fair Value Hierarchy – GMP Bio The Company’s investment in the JV is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including projected cash flows and discount rates. The fair value measurement was determined on a recurring basis as of June 30, 2026, and December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period. <p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_gL3FVAALMORAN-HHEGXMR_zNuu2Nf11Ksj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presented the fair value of the Company’s investment in the JV by level within the fair value hierarchy as June 30, 2026: SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVMylf5x0Gn7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkt7pWtQZXod" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEAqqWEm9Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20251231_zDybNhh8qIl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JVMember_zbXfW3JIgkRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of investment in JV</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zVqQmppA1pXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quantitative Information about significant unobservable inputs (Level 3): SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Valuation Technique</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Unobservable Input</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Range</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Revenue growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zOK5jB9QQTkl">(1)% to <span id="xdx_904_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zMK4wwMGNNxf">400%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">EBIT margin</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zMKkErrZnS92">(146)% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zOhWQnowN981">33%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discount rate (WACC)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90E_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputWeightedAverageCostOfCapitalMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zBDpLs1sXwB">21.4%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Terminal growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--TerminalGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zh6MT4RASfrb">3%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Product penetration rates</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zNXMxOdoZAve" title="Fair value unobservable inputs, percentage rate">1% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zBj1RteR8kxg" title="Fair value unobservable inputs, percentage rate">35%, depending on the product</td></tr> </table> The projected revenue growth rates reflected an initial period of accelerated growth associated with the commercialization and market adoption of one product followed by additional products, subsequently followed by a gradual decline as the business matures and reaches a more stable and then stagnant growth phase as generics enter the market. The pharmaceutical industry often exhibits a financial profile characterized by initially negative EBIT margins, transitioning to high or blockbuster EBIT margins over financial projections. This J-curve trajectory is driven by extreme R&D costs, long development timelines and regulatory protection for a successful drug. The discount rate of 21.4% reflects management’s estimate of the JV’s weighted-average cost of capital, considering its early-stage nature, which to a great extent is mitigated by the expedited regulatory pathway to approval that the Company is planning under the 505(b)(2), for all the market risk, and company-specific risk factors. The significant unobservable inputs used in the fair value measurement are inherently uncertain and reflect management’s judgment about the assumptions market participants would use in pricing the asset. The terminal growth rate reflects long-term expectations for the business beyond the projection period. Increases (decreases) in revenue growth rates, EBIT margins, or terminal growth rates could result in a higher (lower) fair value, while increases (decreases) in the discount rate would result in a lower (higher) fair value. Sensitivity and Measurement Uncertainty The fair value of the Company’s investment in the JV is based on significant unobservable inputs and, as a result, is subject to substantial measurement uncertainty. Changes in key assumptions could result in a materially different fair value. For example, a 100 basis point increase in the discount rate could result in a decrease in the estimated fair value of approximately $120 million. The valuation is derived from projected future cash flows, which are inherently uncertain and subject to change due to, among other factors: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV’s ability to successfully execute its business strategy</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Market adoption of its products and services</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Competitive dynamics within the industry</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Changes in macroeconomic conditions and capital markets</td></tr> </table> Given the early-stage nature of the JV and the absence of an active market for its equity interests, the fair value measurement is particularly sensitive to changes in key assumptions, including projected revenue growth rates, profitability, and the discount rate. Accordingly, actual results could differ materially from those reflected in the valuation, and such differences could have a material impact on the Company’s financial position and results of operations in future periods. The valuation does not represent a guaranteed realizable value and may differ significantly from amounts that could be realized in an actual transaction. Restrictions on Transfer The Company’s ownership interest in the Joint Venture is subject to certain contractual restrictions on transfer under the JV Agreement. In accordance with ASU 2022-03 Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, such restrictions were considered in the determination of fair value. Concentration of Credit Risk The Company does not believe that it is exposed to significant concentrations of credit risk related to its investment in the Joint Venture. Additional Considerations The fair value of the Company’s investment reflects its <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z6a4YlrpFc6b" title="Ownership interest">45% ownership interest and may differ from a pro rata share of the JV’s enterprise value due to factors such as lack of control and marketability. Discounts for lack of control and marketability were applied because the valuation was performed on a non-controlling, non-marketable basis, consistent with ASC 820 fair value. ASC 820 reflects a market participant perspective at the enterprise level. While the applied methods (discounted cash flow and Guideline Public Company) already incorporate risk and marketability assumptions, the Company conservatively applied the control and marketability discounts to the valuation. The valuation does not represent a guaranteed realizable value and may differ significantly from amounts that could be realized in an actual transaction. Fair Value Hierarchy – Lunai The Company’s equity investment in Lunai is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including lack of marketability and liquidity conditions and contractual limitation conditions. The fair value of the investment is determined using a market approach that considers the quoted market price of Lunai’s publicly traded common stock, adjusted to reflect the specific rights, preferences, and restrictions associated with the Series B preferred stock. Because significant unobservable inputs are used in determining fair value, the investment is classified as a Level 3 asset within the fair value hierarchy. The Company received convertible preferred stock of Lunai, with a stated value of $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiMember_zZ0EuBQ3n7o1" title="Proceeds from convertible loan">12.5 million. For financial reporting, the fair value of these shares was determined using a market approach based on the market capitalization value of the underlying common stock on an as-converted basis. This baseline value was then adjusted downward to reflect significant unobservable inputs, specifically a discount for lack of marketability and discounts for contractual restrictions. The fair value measurement was determined as of June 30, 2026 only, as no similar transactions were recorded during the year ended December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period. <div id="xdx_C01_gL3FVAALMORAN-HHEGXMR_zZU6EOuHrsNe">The following table presented the fair value of the Company’s equity investment in Lunai Bioworks by level within the fair value hierarchy as of June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_309_134_zDiEGmRIWl29" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zU3E3ekAXJhf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQAj3ywP7R6g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzPG6O7YGMkl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_zqzCwl2WzzY7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zvFU5wYnOKug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of equity investment in Lunai</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zkBcW3IquWU3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of equity investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td></tr> </table> </div> Quantitative Information about significant unobservable inputs (Level 3) The Company first attributed a portion of the value of the market capitalization of Lunai common stock, based on a fully diluted basis including the preferred shares and common shares. The market capitalization of Lunai was the only observable input available and used in the fair market value of the Company’s investment in preferred shares of Lunai Bioworks. The Company then considered the below factors that impacted the liquidity and marketability of the underlying equity interest along with existing contractual restrictions associated with the Lunai Preferred Stock on the date of the closing of the Lunai transaction and then on June 30, 2026. Sensitivity and Measurement Uncertainty The fair value of the Company’s investment in Lunai is based on significant unobservable inputs and, as a result, is subject to substantial measurement uncertainty. Changes in key assumptions could result in a different fair value. For example, a 10 percent increase in the discount rate could result in a decrease in the estimated fair value of approximately $0.1 million. Lack of liquidity and marketability The Company’s ownership of the convertible preferred shares of Lunai, even if converted into common shares of Lunai, is faced with liquidity and marketability limitations. The common stock of Lunai is fairly thinly traded. Further the preferred shares have Rule 144 restrictions and are restricted in book entry form, have no DTC eligibility, require shareholders’ approval prior to conversion amongst other conditions. The Company attributed a <span id="xdx_90E_ecustom--FairValueInputsDiscountRate_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember_zJaOfgWlqnBe" title="Discount rate">35% discount due to all these factors. Contractual Risks The Company believes that it is exposed to certain concentrations of credit risk related to its investment in the Lunai preferred shares, such as beneficial ownership limitation, suspended conversion, cancellation of the shares if there were an IP clawback, cancellation of shares in the event of indemnification claims among other conditions. The Company attributed a <span id="xdx_90F_ecustom--FairValueInputsDiscountRateLimitations_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember_zP9bx4d8Zce9" title="Discount rate limitations">10% discount for these limitations Based on the above limitations, the Company recorded an initial fair value of $1.1 million for the investment in Lunai on the date of the Lunai merger transaction and further recorded a gain in the value of $0.3 million in the three and six months ended June 30, 2026, based on changes to the fair value inputs. The Company will continue to record the fair value of its investment in future periods on a similar basis and report the change a in fair value through the unaudited condensed consolidated statement of operations. For more information on Lunai, refer to Note 9 – Lunai Bioworks Transactions to these Notes to the unaudited Condensed Consolidated Financial Statements below. Derivative Liability Related to 2019 Bridge Financing The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), consisting of conversion feature derivatives at June 30, 2026 and December 31, 2025, and are Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 for the below periods: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zfTmtesokGm9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zoqnkWOc1HIa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zDDJ7TAzuFUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2026 and 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,044</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,617</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zXlcm52IDIzi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,788</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(353,573</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zU2fa1tk1C65" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026 and December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">337,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of June 30, 2026 and December 31, 2025, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consist, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of June 30, 2026 and December 31, 2025: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk free interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zdsywgFb0URb" title="Risk free interest">3.68% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zMuhPM9VhtZ4" title="Risk free interest">3.98</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zCfmqZYWjMzd" title="Risk free interest">3.48% - <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zHkArOgbcjql" title="Risk free interest">4.03</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zZm2CAhASiEi" title="Market price of share">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zVDsE3MGzYL7" title="Market price of share">0.04 - <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zcqR1acMSCt4" title="Market price of share">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Life of instrument in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20260101__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zCKjKXo7Hcic" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zX76gy8OkJoh" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zgUcy1flsAAf" title="Volatility">108.70%-<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zNeeJjh487c1" title="Volatility">113.14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxC7EKWzrM9k" title="Volatility">114.47%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zRIdNC7B8w4k" title="Volatility">139.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zuf1NJl1Adei" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSFGu9kOaMGl" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td></tr> </table> A contingent consideration liability of $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20260101__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMergerMember_zgJwQYzDLfZk" title="Contigent consideration"><span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMergerMember_zPQGp2sA9ut" title="Contigent consideration">2,625,000 for shares of the Company, issuable to PointR’s shareholders recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic as well as other AI technologies. As such, the Company did not record any change to the valuation as of June 30, 2026. If and when the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period when the transfers occur. For the periods ended June 30, 2026 and June 30, 2025, there were no transfers of financial assets or financial liabilities between the hierarchy levels. Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. For the three months ended June 30, 2026, we included <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zp1q8prHTOn6" title="Common stock equivalents shares">20,527,660 of Common Stock Equivalents related to the convertible notes, to the weighted average Common Stock, as we reported a gain of approximately $<span id="xdx_90A_ecustom--WeightedAverageCommonStock_pn5n6_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zhf9EEJrFw8b" title="Weighted average common stock">0.4 million during such period. For the three months ended June 30, 2025, we included <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zs9yrZVpLsY" title="Common stock equivalents shares">44,516,338 of Common Stock Equivalents, related to the convertible notes, to the weighted average Common Stock, as we reported a gain of approximately $<span id="xdx_902_ecustom--WeightedAverageCommonStock_pn5n6_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zIqYXk8yLDka" title="Weighted average common stock">0.3 million during such period. For the six months ended June 30, 2026 and 2025, respectively, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpBzNWXo0fU3" title="Common stock equivalents shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z39U4jVedbP8" title="Common stock equivalents shares">no equivalent shares of the Common Stock were included as the Company incurred losses during the said periods, because addition of such stock equivalents in the computation would have been anti-dilutive. Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees, including employee stock options, in the statements of operations. For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. For shares issued in connection with provision of services, the Company estimates the cost of the shares at the price of the Company’s stock on the date of issuance and records that cost as a stock-based compensation cost. Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and six months ended June 30, 2026 and 2025, there were no impairment losses recognized for long-lived assets. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the intangible asset’s carrying amount exceeds its fair value, an impairment loss is recognized for the difference. For the three and six months ended June 30, 2026 and 2025, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. Goodwill Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test may be initiated by performing an optional qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is not more likely than not that the fair value is less than the carrying amount, further quantitative testing is not required. Otherwise, a quantitative impairment test is performed by comparing the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. For the three and six months ended June 30, 2026, and 2025, no impairment was recognized toward goodwill. For more information on goodwill and impairment, refer to Note 3 to these Notes to the unaudited Condensed Consolidated Financial Statements. Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Condensed Consolidated Statements of Operations. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”). ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability. Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At June 30, 2026 and December 31, 2025, the Company identified EdgePoint as the Company’s sole VIE. At June 30, 2026 and December 31, 2025, the Company’s ownership percentage of EdgePoint was 29%, respectively. The VIE’s net assets were less than $0.1 million at June 30, 2026 and December 31, 2025, respectively. Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the unaudited condensed consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the unaudited Condensed Consolidated Financial Statements. Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non- managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise considerable influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our unaudited condensed consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our unaudited condensed consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the Company. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. While the Company entered into the transactions with Lunai and recorded service revenue of approximately $0.3 million, the Company does not anticipate generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements, as least in the near future. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized. Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred. Recent Accounting Pronouncements Recently Adopted In December 2023, the FASB issued ASU 2023-09, “Improvements to Tax Disclosures” (Topic 740). The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures through changes to the rate reconciliation and the income taxes paid information disclosed. The ASU is effective prospectively for fiscal years beginning after December 15, 2024, with retrospective application and early adoption permitted. The Company adopted this ASU on a prospective basis as of December 31, 2025 Not Yet Adopted In November 2024 and January 2025, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40) “Disaggregation of Income Statement Expenses” and ASU 2025-01 “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40): Clarifying the Effective Date”. The new guidance is intended to enhance transparency and disclosures by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for the first annual reporting periods after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of evaluating the impact that the adoption of this ASU will have on its financial statements and related disclosures. All other newly issued, but not yet effective, accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Use of Estimates The preparation of financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and related valuation allowance, and fair value of financial instruments.

Cash and Restricted Cash As of June 30, 2026, and December 31, 2025, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2026, and December 31, 2025. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.

Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring.

Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets or liabilities at June 30, 2026 and December 31, 2025.

Investment in equity securities The Company holds equity investments in GMP Bio and Lunai Bioworks Inc. that do not result in a controlling financial interest or significant influence. The Company has elected the fair value option under ASC 825, Financial Instruments. Consequently, these investment are carried at fair value on the unaudited Condensed Consolidated Balance Sheets, with all subsequent changes in fair value recognized immediately in earnings under ASC 321. Unrealized gains and losses resulting from changes in fair value are reported within other income (expense), net on the unaudited Condensed Consolidated Statements of Operations. Below is the change in the fair value of the Company’s equity investments for the six months ended June 30, 2026 and the Audited Consolidated Statements of Operations for the year ended December 31, 2025: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Investment in GMP Bio (JV)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zubIVfEvBCVc" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zl7eWKqfuUqa" style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_z5Equ1s1ZCj8" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Investment Lunai</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zvoFQeoz9God" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, initial book value">1,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zsbtUiqHzQL3" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, unrealized gains">300,000</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zwaCwv3xjDg9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, fair value">1,400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630_zd86mSgKgQKi" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">389,100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630_zPkeim4GxsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">300,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630_zJ5MlgdcJom5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">389,400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (JV)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zsqLcwXhtSgi" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zDvYXnlmzvCg" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">365,346,775</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zJlZNOFyBfLj" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">388,000,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231_zn5UJ541cM4f" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231_zVCBfOqqg29f" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">365,346,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231_zzaXBKRT9FC5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of June 30, 2026 and December 31, 2025. During the year ended December 31, 2025, there was a change in the long-term value of the Company’s investment in equity securities of GMP Bio and as such has been recorded as above. No similar change in fair value has been recorded in the long-term value of the GMP Bio investment during the six months ended June 30, 2026 as the Company has not observed any qualitative conditions required to record any further changes to the fair value. For more information, see Change in Fair Value of Equity Securities of GMP Bio below. In addition, the Company recorded a $1.1 million initial non-cash gain in exchange for a non-financial asset and a $0.3 million gain from the change in the fair value of the Company’s equity securities in Lunai received during the three and six months ended June 30, 2026. No similar gains were recorded during the comparable periods in prior year. For more information, see Note 9 – Lunai Bioworks Transactions below.

SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Investment in GMP Bio (JV)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zubIVfEvBCVc" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zl7eWKqfuUqa" style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_z5Equ1s1ZCj8" style="width: 11%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Investment Lunai</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zvoFQeoz9God" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, initial book value">1,100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zsbtUiqHzQL3" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, unrealized gains">300,000</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630__us-gaap--FinancialInstrumentAxis__custom--LunaiBioworksIncMember_zwaCwv3xjDg9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment in equity securities, fair value">1,400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCost_iI_c20260630_zd86mSgKgQKi" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">389,100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20260101__20260630_zPkeim4GxsI3" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">300,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260630_zJ5MlgdcJom5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">389,400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Beginning Period Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Adjustment to Fair Value</td><td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ending Period Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (JV)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zsqLcwXhtSgi" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zDvYXnlmzvCg" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">365,346,775</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231__us-gaap--FinancialInstrumentAxis__custom--GMPBiotechnologyLimitedMember_zJlZNOFyBfLj" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">388,000,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_iI_c20251231_zn5UJ541cM4f" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, beginning period fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20251231_zVCBfOqqg29f" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjustment to Fair Value">365,346,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20251231_zzaXBKRT9FC5" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, ending period fair value">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

388000000

1100000

300000

1400000

389100000

300000

389400000

22653225

365346775

388000000

22653225

365346775

388000000

1100000

300000

Change in Fair Value of Equity Securities of GMP Bio On March 31, 2022, the Company entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the Company received a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zqaCiahQA495" title="Ownership percentage">45% ownership interest in the JV. The combined enterprise value of GMP Bio, on the date of the formation of the JV, was approximately $<span id="xdx_904_ecustom--JointVentureCombinedEnterpriseValue_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zNbHt4hQAHWb" title="Joint venture combined enterprise value">50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $<span id="xdx_90B_eus-gaap--JointVentureFormationFairValueOfJointVenture_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z9TyFifMCT8f" title="Fair value of investment in joint venture">22.7 million and the total original capital contributions by Dragon Overseas of approximately $<span id="xdx_902_ecustom--JointVentureOtherParticipantCapitalContribution_iI_pn5n6_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zJ27wDFdbL6j" title="Joint venture other participant capital contribution">27.7 million. As of December 31, 2024, the carrying value of the Company’s investment in GMP Bio was approximately $<span id="xdx_909_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_iI_pn4n6_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z7cuPEQb97dd" title="Carrying value of investment">22.7 million, which was included in Investment in GMP Bio at fair value on the unaudited condensed consolidated balance sheets. The investment in GMP Bio has been accounted for under the fair value method of accounting. Similarly, during the year ended December 31, 2025, the Company determined that a remeasurement of its investment to fair value was appropriate. All the factors described below allowed the Company to form a basis for a triggering event of significant development for the JV and justified the JV, and consequently the Company, to reassess the fair value of the JV. The JV’s principal activities centered on the commercialization of OT-101 for certain oncology indications in the US and looking at other territories as well. In March 2025, the JV successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, the JV plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The JV is also sponsoring investigator-initiated studies for OT-101 for other oncology indications including lung cancer (non-small cell lung cancer- NSCLC- and Mesothelioma.- MPM) and has started clinical development for OT-101 for pancreatic cancer. Over ten patent families have been filed exploiting the central role of TGFB2 as prognostic indicator for cancer survival and one patent family for the intracranial delivery device of brain cancer with issued patent in China and Germany. In addition to OT-101, the JV has developed a nanoparticle platform (“Nano Platform”) that entails the formulation of products in new nanoparticle sizes. The JV anticipates that the Nano Platform may offer superior platform for the absorption of water insoluble drugs across a broad spectrum of cancers. The JV is working on improved formulations for OT-101 with new nanoparticle sizes. In addition, the JV has identified five additional compounds as product candidates on the Nano Platform, including the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV has completed the formulation development of the first product, everolimus for injection. The JV has initiated a global clinical trial for that product, including open patient enrollment in Australia. The JV hopes to complete the Phase 1 trial and to move to a Phase 3 noninferiority trial against Affinitor. Phase 3 trial is slated to initiate within one year with completion and submission for marketing approval no less than three years thereafter.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV is developing palbociclib for injection on the Nano Platform and expects to file the investigational new drug (“IND”) and to initiate a Phase 1 trial in 2026.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV is developing docetaxel and paclitaxel for injection on the Nano Platform and expects to file the IND to initiate a Phase 1 trial for this product candidate in 2026. These are expected to go through the 505(b)2 bioequivalence pathway which should result in rapid entrance into the market</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition, the JV has also identified developing carboplatin and intends to begin the development as soon as the other products clinical trials are under way</td></tr> </table> The DeciparticleTM platform has proven robust and is being expand to other drug candidates through partnering. The platform is protected by more than 15 patent families covering chemical composition, manufacturing, and method of use. The JV built a GMP manufacturing facility in San Diego, California (the “San Diego Facility”). In late 2024, the San Diego Facility was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. A significant portion of the manufacturing for the Nano Platform, including the development of Phase I clinical trial materials, is conducted at the San Diego Facility. Evaluation of larger commercial scale manufacturing is ongoing. In early 2025, the Company entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid IND development platform to support up to 20 IND projects, including INDs developed by the JV. All six of the compounds that the JV is developing are planned to be initiated under these INDs, and are focused on next-generation anticancer agents. During the year ended December 31, 2025, GMP Bio completed an independent third-party valuation by an offshore independent valuation firm, which preliminarily estimated the potential value of the drug pipeline under development at approximately $<span id="xdx_90E_eus-gaap--DevelopmentCosts_pn8n9_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zxpkUc0omFx7" title="Development costs">2.3 billion. This valuation was a non-binding, forward-looking, and based upon a number of assumptions including the successful achievement of clinical, regulatory, and commercial milestones. That valuation was interpreted not to be a current measure of fair value under U.S. GAAP. Although no assurances can be given, GMP Bio currently intends to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the unaudited Notes to the unaudited Condensed Consolidated Financial Statements. The Company then conducted its own independent assessment of the valuation of the JV. The basis for the valuation was reliance on the valuation report of the third party offshore valuation firm, including the financial projection, risks and parameters of assessment as done by the offshore independent valuation firm, and then applying additional independent parameters, like discounts for lack of marketability and lack of control, and other standard discounts, required to adhere to the ASC-compliant standards as generally used in the United States. The Company hired the services of an independent, ASC-compliant valuation firm to review, perform and validate the assumptions considered by the Company and provide an ASC-compliant valuation of the JV under U.S. GAAP standards. The valuation conducted by the independent ASC-compliant valuation firm of the JV was based on various methods compliant with ASC and U. S. GAAP to derive the fair value. The Company then utilized the fair value of GMP Bio, as assessed by the ASC-compliant valuation firm, attributed the ownership percentage of the Company in GMP Bio, to ascertain the Company’s interest in GMP Bio and recorded the resulting gain to the investment in GMP Bio at fair value. As the circumstances related to the JV have not materially changed since December 31, 2025, the Company assessed and determined that no additional fair value adjustment was required during the six months ended June 30, 2026, and hence, the Company has not recorded a change in value of the Company’s interest in the JV. The Company will appropriately adjust the fair value of the interest of the Company’s interest in the JV at the end of future reporting periods and when key value inflection points are met. As many of the inputs considered for the purpose of the valuation are unobservable inputs including, but not limited to, the potential revenue projections, the probability of success, the conduct of the clinical trials under accelerated timelines of approvals by the territorial regulatory bodies similar to the 505(b)(2) pathway under the US FDA regulations, the timing of completion of the clinical trials and approvals of the products, timing of product launches, estimates for working capital, additional research and development and general and administrative expenses, estimated tax rates, interest rates of potential debt and many others. The fair value of the Company’s investment was determined in accordance with ASC 820 Fair Value Measurement and is classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The valuation was performed with the assistance of an independent third-party valuation specialist and utilized an income approach (discounted cash flow method) and market-based approach (guideline public company multiples) and recent transactions, where available, to corroborate the results of the income approach. The final value was then arrived at by calculating the average of the values under the two approaches. The income approach of valuation incorporates assumptions that market participants would use in pricing the asset, including estimates of future financial performance and the selection of an appropriate discount rate. As the circumstances related to the JV have not materially changed since December 31, 2025, and June 30, 2026, the Company assessed and determined that no additional fair value adjustment was required and hence, the Company has not recorded a change in value of the Company’s interest in the JV. Fair Value Hierarchy – GMP Bio The Company’s investment in the JV is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including projected cash flows and discount rates. The fair value measurement was determined on a recurring basis as of June 30, 2026, and December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period. <p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_gL3FVAALMORAN-HHEGXMR_zNuu2Nf11Ksj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presented the fair value of the Company’s investment in the JV by level within the fair value hierarchy as June 30, 2026: SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVMylf5x0Gn7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkt7pWtQZXod" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEAqqWEm9Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20251231_zDybNhh8qIl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JVMember_zbXfW3JIgkRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of investment in JV</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zVqQmppA1pXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quantitative Information about significant unobservable inputs (Level 3): SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Valuation Technique</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Unobservable Input</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Range</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Revenue growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zOK5jB9QQTkl">(1)% to <span id="xdx_904_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zMK4wwMGNNxf">400%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">EBIT margin</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zMKkErrZnS92">(146)% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zOhWQnowN981">33%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discount rate (WACC)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90E_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputWeightedAverageCostOfCapitalMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zBDpLs1sXwB">21.4%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Terminal growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--TerminalGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zh6MT4RASfrb">3%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Product penetration rates</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zNXMxOdoZAve" title="Fair value unobservable inputs, percentage rate">1% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zBj1RteR8kxg" title="Fair value unobservable inputs, percentage rate">35%, depending on the product</td></tr> </table> The projected revenue growth rates reflected an initial period of accelerated growth associated with the commercialization and market adoption of one product followed by additional products, subsequently followed by a gradual decline as the business matures and reaches a more stable and then stagnant growth phase as generics enter the market. The pharmaceutical industry often exhibits a financial profile characterized by initially negative EBIT margins, transitioning to high or blockbuster EBIT margins over financial projections. This J-curve trajectory is driven by extreme R&D costs, long development timelines and regulatory protection for a successful drug. The discount rate of 21.4% reflects management’s estimate of the JV’s weighted-average cost of capital, considering its early-stage nature, which to a great extent is mitigated by the expedited regulatory pathway to approval that the Company is planning under the 505(b)(2), for all the market risk, and company-specific risk factors. The significant unobservable inputs used in the fair value measurement are inherently uncertain and reflect management’s judgment about the assumptions market participants would use in pricing the asset. The terminal growth rate reflects long-term expectations for the business beyond the projection period. Increases (decreases) in revenue growth rates, EBIT margins, or terminal growth rates could result in a higher (lower) fair value, while increases (decreases) in the discount rate would result in a lower (higher) fair value. Sensitivity and Measurement Uncertainty The fair value of the Company’s investment in the JV is based on significant unobservable inputs and, as a result, is subject to substantial measurement uncertainty. Changes in key assumptions could result in a materially different fair value. For example, a 100 basis point increase in the discount rate could result in a decrease in the estimated fair value of approximately $120 million. The valuation is derived from projected future cash flows, which are inherently uncertain and subject to change due to, among other factors: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The JV’s ability to successfully execute its business strategy</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Market adoption of its products and services</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Competitive dynamics within the industry</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Changes in macroeconomic conditions and capital markets</td></tr> </table> Given the early-stage nature of the JV and the absence of an active market for its equity interests, the fair value measurement is particularly sensitive to changes in key assumptions, including projected revenue growth rates, profitability, and the discount rate. Accordingly, actual results could differ materially from those reflected in the valuation, and such differences could have a material impact on the Company’s financial position and results of operations in future periods. The valuation does not represent a guaranteed realizable value and may differ significantly from amounts that could be realized in an actual transaction. Restrictions on Transfer The Company’s ownership interest in the Joint Venture is subject to certain contractual restrictions on transfer under the JV Agreement. In accordance with ASU 2022-03 Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, such restrictions were considered in the determination of fair value. Concentration of Credit Risk The Company does not believe that it is exposed to significant concentrations of credit risk related to its investment in the Joint Venture. Additional Considerations The fair value of the Company’s investment reflects its <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z6a4YlrpFc6b" title="Ownership interest">45% ownership interest and may differ from a pro rata share of the JV’s enterprise value due to factors such as lack of control and marketability. Discounts for lack of control and marketability were applied because the valuation was performed on a non-controlling, non-marketable basis, consistent with ASC 820 fair value. ASC 820 reflects a market participant perspective at the enterprise level. While the applied methods (discounted cash flow and Guideline Public Company) already incorporate risk and marketability assumptions, the Company conservatively applied the control and marketability discounts to the valuation. The valuation does not represent a guaranteed realizable value and may differ significantly from amounts that could be realized in an actual transaction. Fair Value Hierarchy – Lunai The Company’s equity investment in Lunai is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including lack of marketability and liquidity conditions and contractual limitation conditions. The fair value of the investment is determined using a market approach that considers the quoted market price of Lunai’s publicly traded common stock, adjusted to reflect the specific rights, preferences, and restrictions associated with the Series B preferred stock. Because significant unobservable inputs are used in determining fair value, the investment is classified as a Level 3 asset within the fair value hierarchy. The Company received convertible preferred stock of Lunai, with a stated value of $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiMember_zZ0EuBQ3n7o1" title="Proceeds from convertible loan">12.5 million. For financial reporting, the fair value of these shares was determined using a market approach based on the market capitalization value of the underlying common stock on an as-converted basis. This baseline value was then adjusted downward to reflect significant unobservable inputs, specifically a discount for lack of marketability and discounts for contractual restrictions. The fair value measurement was determined as of June 30, 2026 only, as no similar transactions were recorded during the year ended December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period. <div id="xdx_C01_gL3FVAALMORAN-HHEGXMR_zZU6EOuHrsNe">The following table presented the fair value of the Company’s equity investment in Lunai Bioworks by level within the fair value hierarchy as of June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_309_134_zDiEGmRIWl29" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zU3E3ekAXJhf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQAj3ywP7R6g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzPG6O7YGMkl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_zqzCwl2WzzY7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zvFU5wYnOKug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of equity investment in Lunai</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zkBcW3IquWU3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of equity investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td></tr> </table> </div> Quantitative Information about significant unobservable inputs (Level 3) The Company first attributed a portion of the value of the market capitalization of Lunai common stock, based on a fully diluted basis including the preferred shares and common shares. The market capitalization of Lunai was the only observable input available and used in the fair market value of the Company’s investment in preferred shares of Lunai Bioworks. The Company then considered the below factors that impacted the liquidity and marketability of the underlying equity interest along with existing contractual restrictions associated with the Lunai Preferred Stock on the date of the closing of the Lunai transaction and then on June 30, 2026. Sensitivity and Measurement Uncertainty The fair value of the Company’s investment in Lunai is based on significant unobservable inputs and, as a result, is subject to substantial measurement uncertainty. Changes in key assumptions could result in a different fair value. For example, a 10 percent increase in the discount rate could result in a decrease in the estimated fair value of approximately $0.1 million. Lack of liquidity and marketability The Company’s ownership of the convertible preferred shares of Lunai, even if converted into common shares of Lunai, is faced with liquidity and marketability limitations. The common stock of Lunai is fairly thinly traded. Further the preferred shares have Rule 144 restrictions and are restricted in book entry form, have no DTC eligibility, require shareholders’ approval prior to conversion amongst other conditions. The Company attributed a <span id="xdx_90E_ecustom--FairValueInputsDiscountRate_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember_zJaOfgWlqnBe" title="Discount rate">35% discount due to all these factors. Contractual Risks The Company believes that it is exposed to certain concentrations of credit risk related to its investment in the Lunai preferred shares, such as beneficial ownership limitation, suspended conversion, cancellation of the shares if there were an IP clawback, cancellation of shares in the event of indemnification claims among other conditions. The Company attributed a <span id="xdx_90F_ecustom--FairValueInputsDiscountRateLimitations_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember_zP9bx4d8Zce9" title="Discount rate limitations">10% discount for these limitations Based on the above limitations, the Company recorded an initial fair value of $1.1 million for the investment in Lunai on the date of the Lunai merger transaction and further recorded a gain in the value of $0.3 million in the three and six months ended June 30, 2026, based on changes to the fair value inputs. The Company will continue to record the fair value of its investment in future periods on a similar basis and report the change a in fair value through the unaudited condensed consolidated statement of operations. For more information on Lunai, refer to Note 9 – Lunai Bioworks Transactions to these Notes to the unaudited Condensed Consolidated Financial Statements below.

0.45

50400000

22700000

27700000

22700000

2300000000

<p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_gL3FVAALMORAN-HHEGXMR_zNuu2Nf11Ksj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presented the fair value of the Company’s investment in the JV by level within the fair value hierarchy as June 30, 2026: SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVMylf5x0Gn7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkt7pWtQZXod" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEAqqWEm9Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20251231_zDybNhh8qIl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JVMember_zbXfW3JIgkRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of investment in JV</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,000,000</td><td style="width: 1%; text-align: left"> </td></tr> </table> The following table presented the fair value of the Company’s equity investment in Lunai Bioworks by level within the fair value hierarchy as of June 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_309_134_zDiEGmRIWl29" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zU3E3ekAXJhf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQAj3ywP7R6g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzPG6O7YGMkl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_zqzCwl2WzzY7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zvFU5wYnOKug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Fair value of equity investment in Lunai</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InvestmentOwnedAtFairValue_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LunaiBioworksIncMember_zkBcW3IquWU3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of equity investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td></tr> </table>

388000000

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zVqQmppA1pXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quantitative Information about significant unobservable inputs (Level 3): SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Valuation Technique</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Unobservable Input</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Range</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Revenue growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zOK5jB9QQTkl">(1)% to <span id="xdx_904_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zMK4wwMGNNxf">400%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">EBIT margin</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zMKkErrZnS92">(146)% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEbitdaMultipleMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zOhWQnowN981">33%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Discount rate (WACC)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90E_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputWeightedAverageCostOfCapitalMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zBDpLs1sXwB">21.4%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Terminal growth rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--TerminalGrowthRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember_zh6MT4RASfrb">3%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Discounted Cash Flow</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Product penetration rates</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MinimumMember_zNXMxOdoZAve" title="Fair value unobservable inputs, percentage rate">1% to <span id="xdx_903_ecustom--FairValueUnobservableInputsPercentageRate_iI_pid_dp_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--ProductPenetrationRatesMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueDiscountedCashFlowMember__srt--RangeAxis__srt--MaximumMember_zBj1RteR8kxg" title="Fair value unobservable inputs, percentage rate">35%, depending on the product</td></tr> </table>

-0.01 4 -1.46 0.33 0.214 0.03 0.01 0.35 0.214 120000000

0.45

12500000

1400000

100000 0.35 0.10 1100000

300000

Derivative Liability Related to 2019 Bridge Financing The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), consisting of conversion feature derivatives at June 30, 2026 and December 31, 2025, and are Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 for the below periods: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zfTmtesokGm9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zoqnkWOc1HIa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zDDJ7TAzuFUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2026 and 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,044</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,617</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zXlcm52IDIzi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,788</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(353,573</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zU2fa1tk1C65" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026 and December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">337,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of June 30, 2026 and December 31, 2025, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consist, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of June 30, 2026 and December 31, 2025: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk free interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zdsywgFb0URb" title="Risk free interest">3.68% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zMuhPM9VhtZ4" title="Risk free interest">3.98</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zCfmqZYWjMzd" title="Risk free interest">3.48% - <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zHkArOgbcjql" title="Risk free interest">4.03</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zZm2CAhASiEi" title="Market price of share">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zVDsE3MGzYL7" title="Market price of share">0.04 - <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zcqR1acMSCt4" title="Market price of share">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Life of instrument in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20260101__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zCKjKXo7Hcic" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zX76gy8OkJoh" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zgUcy1flsAAf" title="Volatility">108.70%-<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zNeeJjh487c1" title="Volatility">113.14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxC7EKWzrM9k" title="Volatility">114.47%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zRIdNC7B8w4k" title="Volatility">139.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zuf1NJl1Adei" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSFGu9kOaMGl" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td></tr> </table> A contingent consideration liability of $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20260101__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMergerMember_zgJwQYzDLfZk" title="Contigent consideration"><span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMergerMember_zPQGp2sA9ut" title="Contigent consideration">2,625,000 for shares of the Company, issuable to PointR’s shareholders recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic as well as other AI technologies. As such, the Company did not record any change to the valuation as of June 30, 2026. If and when the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period when the transfers occur. For the periods ended June 30, 2026 and June 30, 2025, there were no transfers of financial assets or financial liabilities between the hierarchy levels. SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zfTmtesokGm9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20251231_zoqnkWOc1HIa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025 Conversion Feature</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zDDJ7TAzuFUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2026 and 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">350,044</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,617</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zXlcm52IDIzi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,788</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(353,573</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zU2fa1tk1C65" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026 and December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">337,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

350044

703617

-12788

-353573

337256

350044

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk free interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zdsywgFb0URb" title="Risk free interest">3.68% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zMuhPM9VhtZ4" title="Risk free interest">3.98</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zCfmqZYWjMzd" title="Risk free interest">3.48% - <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zHkArOgbcjql" title="Risk free interest">4.03</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zZm2CAhASiEi" title="Market price of share">0.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zVDsE3MGzYL7" title="Market price of share">0.04 - <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zcqR1acMSCt4" title="Market price of share">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Life of instrument in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20260101__20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zCKjKXo7Hcic" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20250101__20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zX76gy8OkJoh" title="Life of instrument in years">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zgUcy1flsAAf" title="Volatility">108.70%-<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zNeeJjh487c1" title="Volatility">113.14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxC7EKWzrM9k" title="Volatility">114.47%-<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zRIdNC7B8w4k" title="Volatility">139.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zuf1NJl1Adei" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zSFGu9kOaMGl" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td></tr> </table>

3.68

3.98

3.48

4.03

0.04

0.08

P0Y3D P0Y3D

108.70

113.14

114.47

139.5

2625000

Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. For the three months ended June 30, 2026, we included <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zp1q8prHTOn6" title="Common stock equivalents shares">20,527,660 of Common Stock Equivalents related to the convertible notes, to the weighted average Common Stock, as we reported a gain of approximately $<span id="xdx_90A_ecustom--WeightedAverageCommonStock_pn5n6_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zhf9EEJrFw8b" title="Weighted average common stock">0.4 million during such period. For the three months ended June 30, 2025, we included <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zs9yrZVpLsY" title="Common stock equivalents shares">44,516,338 of Common Stock Equivalents, related to the convertible notes, to the weighted average Common Stock, as we reported a gain of approximately $<span id="xdx_902_ecustom--WeightedAverageCommonStock_pn5n6_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zIqYXk8yLDka" title="Weighted average common stock">0.3 million during such period. For the six months ended June 30, 2026 and 2025, respectively, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpBzNWXo0fU3" title="Common stock equivalents shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z39U4jVedbP8" title="Common stock equivalents shares">no equivalent shares of the Common Stock were included as the Company incurred losses during the said periods, because addition of such stock equivalents in the computation would have been anti-dilutive.

20527660

400000

44516338

300000

Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees, including employee stock options, in the statements of operations. For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. For shares issued in connection with provision of services, the Company estimates the cost of the shares at the price of the Company’s stock on the date of issuance and records that cost as a stock-based compensation cost.

Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and six months ended June 30, 2026 and 2025, there were no impairment losses recognized for long-lived assets.

Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the intangible asset’s carrying amount exceeds its fair value, an impairment loss is recognized for the difference. For the three and six months ended June 30, 2026 and 2025, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed.

Goodwill Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test may be initiated by performing an optional qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is not more likely than not that the fair value is less than the carrying amount, further quantitative testing is not required. Otherwise, a quantitative impairment test is performed by comparing the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. For the three and six months ended June 30, 2026, and 2025, no impairment was recognized toward goodwill. For more information on goodwill and impairment, refer to Note 3 to these Notes to the unaudited Condensed Consolidated Financial Statements.

Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Condensed Consolidated Statements of Operations.

Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”). ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability.

Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At June 30, 2026 and December 31, 2025, the Company identified EdgePoint as the Company’s sole VIE. At June 30, 2026 and December 31, 2025, the Company’s ownership percentage of EdgePoint was 29%, respectively. The VIE’s net assets were less than $0.1 million at June 30, 2026 and December 31, 2025, respectively.

0.29

100000

Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the unaudited condensed consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the unaudited Condensed Consolidated Financial Statements.

Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non- managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise considerable influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our unaudited condensed consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our unaudited condensed consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the Company.

Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. While the Company entered into the transactions with Lunai and recorded service revenue of approximately $0.3 million, the Company does not anticipate generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements, as least in the near future. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

300000

Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Recent Accounting Pronouncements Recently Adopted In December 2023, the FASB issued ASU 2023-09, “Improvements to Tax Disclosures” (Topic 740). The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures through changes to the rate reconciliation and the income taxes paid information disclosed. The ASU is effective prospectively for fiscal years beginning after December 15, 2024, with retrospective application and early adoption permitted. The Company adopted this ASU on a prospective basis as of December 31, 2025 Not Yet Adopted In November 2024 and January 2025, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40) “Disaggregation of Income Statement Expenses” and ASU 2025-01 “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40): Clarifying the Effective Date”. The new guidance is intended to enhance transparency and disclosures by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for the first annual reporting periods after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of evaluating the impact that the adoption of this ASU will have on its financial statements and related disclosures. All other newly issued, but not yet effective, accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

NOTE 3 - ACQUISITIONS, GOODWILL AND INTANGIBLE ASSETS Goodwill from 2019 Reverse Merger with Oncotelic and Merger with PointR The Company completed the reverse merger with Oncotelic Inc. (“Merger”) in April 2019. The Company completed the merger with PointR Data Inc (“PointR Merger”) in November 2019. For more details on the two mergers, refer to our 2020 Annual Report on Form 10-K for the year ended December 31, 2020 filed by the Company on April 15, 2021. The Oncotelic merger gave rise to Goodwill of approximately $4.9 million. Upon the non-financial sale of our asset as contribution to our equity method investment, we derecognized the balance of the carrying value of our goodwill of approximately $4.9 million from the Oncotelic Merger in accordance with our policy and authoritative accounting guidance. Further, we added goodwill of approximately $16.2 million upon the completion of the Merger with PointR. Between the years 2022 and 2024, we recorded impairments of approximately $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_pn5n6_c20220101__20241231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PointRMember_zNdxAz9d7ynk" title="Asset impairment charges">13.4 million, as we observed our market capitalization being negatively impacted as compared to the book value of our net assets. We have one operating segment and reporting unit. Accordingly, our review of goodwill impairment indicators was performed at the entity-wide level. In performing our annual impairment assessment, we determined if we should qualitatively assess whether it was more likely than not the fair value of goodwill was less than its carrying amount (the qualitative impairment test). The factors we considered in the assessment included our market capitalization, general macroeconomic conditions, conditions specific to the industry and market and whether there had been sustained declines in our share price. If we concluded, it was more likely than not, the fair value of the reporting unit was less than its carrying amount, or elected not to use the qualitative impairment test, a quantitative impairment test would be performed. We have used our market capitalization as an indicator of fair value. While we believe the fair value measurement need not be based solely on the quoted market price of an individual share of our Common Stock, and that we also could consider the impact of a control premium in measuring the fair value of its reporting unit. In the absence of any other valuation metrics, the Company believed using a control premium utilized would not be appropriate under the current circumstances. We also considered some other market comparables’ trends in our stock price as well as the industry over a period of two successive quarters and prospective quarter to evaluate whether the fair value of our reporting unit was greater than our carrying amount. No impairment to goodwill was required to be recorded for the year ended December 31, 2025. The Company evaluated if it needed to record any goodwill impairment as of June 30, 2026, based solely on the market capitalization of the Company and concluded that no impairment was required to be recorded for the three and six months ended June 30, 2026. A summary of our goodwill as of June 30, 2026, and December 31, 2025, is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260630_zBpTOTrZ2Uw" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20251231_znyuWTlYFykk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zgfQwKyfa494" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2026 and 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_z4WMVMA7ypC" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_z8G7UCrR95A" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026 and December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Goodwill is tested for impairment annually as of December 31, or more frequently if events or changes in circumstances, such as a sustained decline in our market capitalization, indicate that it is more likely than not that the fair value of a reporting unit is below its carrying amount. If an interim evaluation indicates that an impairment exists, a quantitative test is performed, and any resulting impairment loss is recognized in the period identified In-Process Research & Development (“IPR&D”) Summary The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of June 30, 2026 and December 31, 2025, respectively, was $<span id="xdx_90B_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_c20260630__custom--StatementsOfIncomeLocationBalanceAxis__us-gaap--InProcessResearchAndDevelopmentMember_zM2T8jZHjDdg" title="Intangible asset, net"><span id="xdx_90F_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_c20251231__custom--StatementsOfIncomeLocationBalanceAxis__us-gaap--InProcessResearchAndDevelopmentMember_zkuGHhMtUdb7" title="Intangible asset, net">1,101,760. For more information on the IPR&D, please refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. The Company did not record any impairment as of June 30, 2026 and December 31, 2025.

4900000

16200000

13400000

A summary of our goodwill as of June 30, 2026, and December 31, 2025, is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260630_zBpTOTrZ2Uw" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20251231_znyuWTlYFykk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zgfQwKyfa494" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2026 and 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_z4WMVMA7ypC" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_z8G7UCrR95A" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026 and December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2788230

1101760

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities consist of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zCyJ7eJdNzP6" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zgWfVrgPb3Sl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_zZHasEqHVgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,834,965</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,638,713</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_zjyTtsFLNJZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">720,034</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">932,410</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_zF6g1ArmZHL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,554,999</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,571,123</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_za3Yn8tjOrZb" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zeX4Zcar05D5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zybhiW2kTc0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts payable – related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,138</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">348,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued liabilities consist of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630_zCyJ7eJdNzP6" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zgWfVrgPb3Sl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_zZHasEqHVgZd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,834,965</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,638,713</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_zjyTtsFLNJZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">720,034</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">932,410</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_zF6g1ArmZHL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,554,999</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,571,123</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_za3Yn8tjOrZb" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zeX4Zcar05D5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zybhiW2kTc0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts payable – related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,138</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">348,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1834965

1638713

720034

932410

2554999

2571123

349138

348111

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT As of June 30, 2026, and December 31, 2025, special purchase agreements (“SPAs”) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_zT65nVLnhiLc" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_z21GNaiIUJgk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zcTG2MJiRyla" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zGlulO3DPMtg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zI1g9JaTs6Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zbn4XOHXckck" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zsjb08RWnIU1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z11xXIOJ94Z" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">326,233</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zRWhbya5DYF1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zSolYGwbhzh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,759</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zh2vRJyhhBb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">222,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">218,722</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zT6gBuGMEeHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,137,675</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,116,425</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_z17T3XYT6iPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,052</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zM2sApQksNy" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,751</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zdKjOH3AGB95" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">93,398</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91,522</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zptCte34Dm8b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">869,789</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">852,325</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zQ2RM91XRyv2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">61,480</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,531</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Debt for Clinical Trials – Forever Prosperity ( Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zBqCoOBca5kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,974,877</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,930,247</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">May 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_z3ZjmalpPHub" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">809,492</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">J.H. Darbie PPM-2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--AccruedAndUnpaidInterestMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zEmJKTVsXz5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued and Unpaid Interest – PPM-2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,111</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">102,795</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">July 2025 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyFiveNoteMember_zk61aBzomuQf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">595,179</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">465,261</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">January 2026 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentySixNoteMember_zqNx7fmwuq8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note - Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">314,153</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Pacific Pier 2026 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--PacificPierTwoThousandTwentySixNoteMember_zip3Jj50rxDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">12% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">129,450</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Other Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z3VefZl2bmF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z0kGAx7Aspn3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zWchVUpsTbH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,067,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,992,874</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zqIsZcPAkuM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term Debt from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAccreditedInvestorMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z39axcxQW5ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short-term loan from Accredited investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zhB0uhrxa5Zj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,538,851</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,513,924</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleDebtCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ziX2aXfksD89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible and short-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,925,881</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,225,669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNvVDUpG2xAi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible debt and short-term debt – related party, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,114,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,023,331</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630_z8Vs0k6kHej1" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zs1gwdtlAK59" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; width: 60%; font-weight: bold; text-align: left">Long Term Debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">12% convertible note - JH Darbie PPM-3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM3DebtMember_zj00NYIJBqQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM3DebtMember_zfcJJP0UgP9i" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Convertible Note payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convertible Debentures As of June 30, 2026, the Company had a derivative liability of approximately $<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20260630__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebenturesMember_zVz5AGJojGw2" title="Derivative liability">337,200 and recorded a change in fair value of approximately $<span id="xdx_907_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pp0p0_c20260630__us-gaap--ShortTermDebtTypeAxis__custom--BridgeInvestorMember_zZfxqiYQPx44" title="Credit risk derivative liabilities, at fair value">12,800 on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. As of December 31, 2025, the Company had a derivative liability of approximately $<span id="xdx_90F_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20251231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebenturesMember_zgr74g88r0Zd" title="Derivative liability">350,000 and recorded a change in fair value of approximately $<span id="xdx_90F_eus-gaap--CreditRiskDerivativeLiabilitiesAtFairValue_iI_pp0p0_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--BridgeInvestorMember_z8u2yKVwybh4" title="Credit risk derivative liabilities, at fair value">353,600 during the year ended December 31, 2025, on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. Bridge Financings Notes with Officer and Bridge Investor In April 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO and the Bridge Investor with a commitment to purchase convertible notes in the aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSvJDU3XtrDa">400,000. For more information on the Bridge SPA, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. In April 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. For more information on Tranche #1, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. In August 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. For more information on Tranche #2, refer to 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. Fall 2019 Debt Financing In December 2019, the Company closed its Fall 2019 Debt Financing, raising an additional $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20191201__20191231__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenDebtFinancingMember_zBujXxuxSKYe" title="Gross proceeds from convertible debt">500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. The Company issued Fall 2019 Notes in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zgy5y0QcDbA1" title="Principal amount">250,000 to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $<span id="xdx_90D_ecustom--ProceedsFromConvertibleDebtGross_pp0p0_c20191231__20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zPQCCmULAGPj" title="Gross proceeds">500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, the Company issued Fall 2019 Notes to additional investors including $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrSanjayJhaMember_zmtHwE1Uo9Ui" title="Debt instrument face amount">250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s then Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer, all related parties as Officers of the Company, and converted such amounts due into the Fall 2019 Notes. $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIKots4iFSE" title="Related parties">35,000 due to Dr. Vuong Trieu, $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--ChulhoParkMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4WnRz178qkb" title="Related parties">27,000 due to Chulho Park and $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--AmitShahMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJDiJCzwpBVi" title="Related parties">20,000 due to Amit Shah were converted into convertible debt under the Fall 2019 Notes. The Company also issued a total of the Fall 2019 Notes of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorsMember_zLs70mre8sL4" title="Debt instrument face amount">168,000 to two accredited investors. All the Fall 2019 Notes provided for interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260630__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember_zu4mj8ZeXU3a" title="Interest rate">5% per annum and are unsecured. For more information on the Fall 2019 Debt Financing, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. There was no activity during the six months ended June 30, 2026 and 2025. The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of June 30, 2026, and December 31, 2025. Further, the Company recorded interest expense of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_pp0p0_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z7OpMAaHVIr6" title="Interest expense"><span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_ztFm2oCF38zg" title="Interest expense">10,625 and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_pp0p0_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zzOS1MFJaXm4" title="Interest expense"><span id="xdx_901_eus-gaap--InterestExpenseDebt_pp0p0_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zDj4uQTrE5Bi" title="Interest expense">21,250 on these Fall 2019 Notes for the three and six months ended June 30, 2026, and 2025, respectively. The total amount outstanding under the Fall 2019 Notes, net of discounts for both periods, respectively. Forever Prosperity (Formerly GMP) Notes In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and was personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID- 19 bearing 2% annual interest. In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pn5n6_c20211031__us-gaap--TypeOfArrangementAxis__custom--OctoberPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGmvJw55kjic">0.5 million. Further, in January 2022, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “January Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn5n6_c20220131__us-gaap--TypeOfArrangementAxis__custom--JanuaryPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zPao0lEevZil">0.5 million. Cumulatively, these four Notes are referred to as the “GMP Notes”. The GMP Notes carry an interest rate of 2% per annum and mature on the earlier of (a) the one- year anniversary of the date of the Purchase Agreement, or (b) the acceleration of the maturity by GMP upon occurrence of an Event of Default (as defined below). All Notes contain a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of all the GMP Notes into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion from GMP. Prepayment of the GMP Notes may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. As of June 30, 2026, the GMP Notes are in default, however Forever Prosperity has not called for the repayment of the debt. The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $5.0 million as of June 30, 2026, and approximately $4.9 million as of December 31, 2025. During the three and six months ended June 30, 2026, and 2025, respectively, the Company incurred approximately $22,000 and $44,600 of interest expense, respectively, on all the 4 notes. For a more detailed discussion on the Forever Prosperity Notes, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. August 2021 Notes In August 2021, the Company entered into Note Purchase Agreements with Autotelic - a related party, our CFO – a related party, and certain accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into shares of common stock of the Company for net proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zt4ajhbeCfXh" title="Proceeds from issuance of common stock">691,000. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18. The August 2021 Note Holders has waived the default in the maturity of the August 2021 Notes and as such there is no event of default and also agreed to extend the date of maturity of the August 2021 Notes to December 31, 2026. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity. <p id="xdx_898_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-VWTYID_zO2VfJcJW234" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The August 2021 convertible notes, inclusive of accrued interest, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zTe6t1vuP074" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_z54X0F9bntYh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zuFTuFEF0lg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Autotelic - Related party convertible note, 5% coupon December 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">311,302</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">305,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zw2Rp1mHt5Eg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CFO - Related party convertible note, 5% coupon December 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zMNTDwT8q9X8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accredited investors convertible note, 5% coupon December 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">465,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">455,751</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zev9mMGF4D0g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total August 2021 convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">869,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">852,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three and six months ended June 30, 2026 and 2025, respectively, the Company recognized approximately $8,700 and approximately $17,500 of interest expense on the August 2021 convertible notes, of which approximately $4,000 and approximately $8,100 are attributable to related parties. At June 30, 2026, and December 31, 2025, accrued interest on these convertible notes totaled approximately $0.2 million. March 2022 Financing In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zXZOVi0Ajb65" title="Debt instrument, face amount">0.25 million, convertible into shares of common stock of the Company. The convertible notes carry a twelve (<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_z439poMwq2qh" title="Interest rate">12%) percent coupon and a default coupon of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zlA9nQZU9iM4" title="Interest rate, effective percentage">16% and mature at the earliest of one year from issuance or upon event of default. As of December 31, 2023, this note was in default and Fourth Man has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at an initial conversion price established at a fixed rate of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_ztuTT6GJsFA7" title="Debt conversion price">0.10, and subsequently corrected to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260401__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zkoktStT6nN3" title="Debt conversion price">0.07 based on the terms of the Securities Purchase Agreement and Fourth Man Note. The Company granted a total number of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_z3htKZbAI5Hi" title="Convertible warrants">1,250,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zzsRhIrxH09h" title="Share price">0.20 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260630__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4IvKpzOlLB3" title="Shares granted">125,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zY6WSRxq5bmc" title="Debt conversion price">0.20 up to five years after issuance, as part of a finder’s fee agreement. <div id="xdx_C05_gL3SOCNNODTTB-VWTYID_zqORGUkjlVWe">The March 2022 Fourth Man convertible note, including accrued interest and net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zzJtwrlEJeR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260630__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zB2tCiVz94Kh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_znbm5OfuiLbl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zhybGRdwW54b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61,480</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,531</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_hus-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zSVnM43fGtm3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zDvighxiVdF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">61,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">58,531</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> During the year ended December 31, 2025, the Company converted approximately $150,000 in principal and approximately $54,100 in accrued interest and legal fees into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj1UwtEb64T" title="Convertible notes into common stock, shares">2,991,270 shares of common stock. The note includes a default amount calculated at <span id="xdx_90D_ecustom--DebtDefaultPrincipalAndAccruedInterestPercentage_iI_pid_dp_uPure_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakeMember_zlFkXI3fzib4" title="Debt default principal and accrued interest percentage">125% of the unpaid principal and accrued interest. As the Company failed to repay the note at the original maturity date, the Company has recorded an estimated default penalty of approximately $<span id="xdx_907_ecustom--EstimatedDefaultPenalty_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakeMember_ziGtsB8O1UPe" title="Estimated default penalty">70,000. In April 2026, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260401__20260430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakeMember_zOyyNNsy15g2">300,000 shares to Fourth Man in exchange for a one-time waiver of their right to adjustment of conversion price of their March 2022 note. The Company recognized approximately $2,500 and $5,000 of interest during the three and six months ended June 30, 2026. Similarly, the Company recognized approximately $8,200 and $15,400 of interest during the three and six months ended June 30, 2025. May 2022 Mast Financing In May 2022, the Company entered into a securities purchase agreement with Mast Hill, whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zfOr8vvZeiQl" title="Principal amount">605,000 convertible into shares of common stock of the Company (“May 2022 Mast Note”). The convertible notes carry a twelve (<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zhLaLYWNXoi6" title="Interest percentage">12%) percent coupon and a default coupon of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_z7aYSEaD6Ur8" title="Debt instrument interest rate effective percentage">16% and mature at the earliest of one year from issuance or upon event of default. Investor has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_z3hdRwhigZFe" title="Conversion price">0.10. The note is secured against the assets of the Company, excluding any assets assigned to the JV. The Company granted a total number of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zSf8r0yYbbK5" title="Warrants convertible">3,025,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zY7bk1heBcc8" title="Common shares strike price">0.20 up to five years after issuance. The Placement agent was also granted a total amount of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220501__20220531__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVLOC9CvhmUg" title="Granted">302,500 as part of a finder’s fee agreement. Portion of the proceeds were be used to retire some of the November/December 2021 notes. During the year ended December 31, 2025, the Company converted approximately $272,000 in accrued interest and legal fees into 3,860,000 shares of common stock. The May 2022 Mast Note had been extended through May 27, 2025 at a cost of approximately $82,000, and which is included in the amount outstanding and payable to Mast as of December 31, 2025. Mast Hill further extended the May 2022 Mast Note to December 31, 2026 in August 2025. In June 2026, Mast Hill fully converted the balance of their note of approximately $847,000, including principal, accrued interest, default penalty and legal fees, into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pp0p0_c20260601__20260630__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zyQv4TMhIfdb" title="Convertible notes into common stock, shares">11,877,507 common shares of the Company. <div id="xdx_C07_gL3SOCNNODTTB-VWTYID_z1UiSuuU5Yj5">The May 2022 Mast Financing, net of debt discount, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_307_134_zLFNdWhCkpta" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zKrXsMdClI4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zeXzIZyXkC47" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_hdei--LegalEntityAxis__custom--MastHillMember__us-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_zroIwWtQ3pG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">809,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_zN0IWxmoXcs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total May 2022 convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">809,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The Company the original debt discount, deferred financing costs, fair value allocated to the warrants during the three and six months ended June 30, 2026, respectively. July 2025 Mast Financing In July of 2025, the Company entered into a securities purchase agreement with Mast Hill, whereby the Company issued a secured convertible note in the aggregate principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zu47zZbYbZt8" title="Principal amount">560,000 convertible into shares of Common Stock of the Company (“July 2025 Mast Note”). The July 2025 Mast Note carries a twelve (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_ztpxOjOsB246" title="Debt interest rate">12%) percent coupon and a default coupon of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zyUaueqRqfX8" title="Debt instrument interest rate effective percentage">18% and mature at the earliest of one year from issuance or upon event of default. Mast Hill has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at a conversion price established at a fixed rate of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zplEIkrDI7Xc" title="Conversion price">0.07. The July 2025 Mast Note is secured against the assets of the Company, excluding any assets assigned to the JV. In connection with the July 2025 Mast Note, the Company granted a total number of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_z4rWAwVqX9tj" title="Granted total number of warrants">2,000,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $0.15 up to five years after issuance. The Company also issued 2,250,000 of the Company’s common stock as commitment shares to Mast. Mast has agreed to extend the July 2025 Mast Note through the end of January 2027. The July 2025 Mast Note, and the May 2022 Note were securitized against all the assets of the Company, excluding the <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20250731__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JVMember_zP0SzYJgDMK3" title="Ownership interest">45% ownership of the Company in the JV, however, Mast Hill fully converted their May 2022 Note. The July 2025 Mast Note, net of debt discount, consists of the following amounts: SCHEDULE OF NET OF DEBT DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20260630__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zsx7vn1tV7he" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20251231__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_znyeWN9ORITj" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponAugustTwoThousandTwentySixMember_zYyOG0GWBoOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Mast Hill Convertible note, inclusive of accrued interest 12% coupon due January 2027, gross</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">611,511</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">583,512</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zucl2GE2y5Wg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Less: debt discount recorded</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(203,833</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(203,833</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zvCFMog0M5C5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Amortization of debt discount</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">187,501</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">85,582</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zrAlwSvZg4F4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible notes, net</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">595,179</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">465,261</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> The Company recognized approximately $14,000 and $28,000 of accrued interest during the three and six months ended June 30, 2026. It recognized $0 of accrued interest during the same period in 2025. The Company recognized approximately $<span id="xdx_907_eus-gaap--InterestExpenseDebtExcludingAmortization_pp0p0_c20260401__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JulyTwoThousandAndTwentyFiveMember_z8AbdVcMX7p1" title="Interest expense, debt, excluding amortization">51,000 and $<span id="xdx_90B_eus-gaap--InterestExpenseDebtExcludingAmortization_pp0p0_c20260101__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JulyTwoThousandAndTwentyFiveMember_zskmXLyMI0Jf" title="Interest expense, debt, excluding amortization">102,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the three and six months ended June 30, 2026, as opposed to $<span id="xdx_90C_eus-gaap--InterestExpenseDebtExcludingAmortization_pp0p0_c20250101__20251231__us-gaap--ShortTermDebtTypeAxis__custom--JulyTwoThousandAndTwentyFiveMember_z3yNPfrndDm6" title="Interest expense, debt, excluding amortization">0 during the same period in 2025. January 2026 Mast Financing In January of 2026, the Company entered into a securities purchase agreement with Mast, whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_z8oeA7HaC0si">398,333 convertible into shares of common stock of the Company (“2026 Mast Note”). The convertible notes carry a ten (<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zGSbyXjdSUNl">10%) percent coupon and a default coupon of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zvmPy5nvDqg7">18% and mature at the earliest of one year from issuance or upon event of default. Mast has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_z0MFzze0lhx1">0.07. The note is secured against the assets of the Company, excluding any assets assigned to the JV. The Company granted a total number of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260123__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zNWfXysvr7d6">1,422,613 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zWA2x8IrNIx4" title="Share price">0.15 up to five years after issuance. The Company also issued 1,600,446 of the Company’s common stock as commitment shares to Mast. The 2026 Mast Note was securitized against all the assets of the Company, excluding the 45% ownership of the Company in the JV. <div id="xdx_C0D_gL3SODTTB-TUXY_z5aliHNbRrmc">The convertible note under the 2026 Mast Note, net of debt discount, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30D_134_zbkX9BwrTEcg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF NET OF DEBT DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zaLkPl2JrkY4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zaNSWNO1v3ee" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponJanuaryTwoThousandTwentySevenMember_zqAudzE0OwY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, inclusive of accrued interest 10% coupon January 2027, gross</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">415,603</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zm7hIqJtBX8j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(179,102</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zFotLHSeTzfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">77,652</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zhJrlDr4MSg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">314,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The Company recognized approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20260401__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zVp77cETbQtg" title="Accrued interest">7,300 and $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20260101__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zlPIzJQk4PBg" title="Accrued interest">17,000 of accrued interest during the three and six months ended June 30, 2026, respectively. There was no similar expense during the same periods in 2025. The Company recognized approximately $<span id="xdx_908_eus-gaap--InterestExpenseDebtExcludingAmortization_pp0p0_c20260401__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_z8ph5V0KNgAb" title="Interest expense, debt, excluding amortization">32,900 and $<span id="xdx_901_eus-gaap--InterestExpenseDebtExcludingAmortization_pp0p0_c20260101__20260630__us-gaap--ShortTermDebtTypeAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_ziP04224GjK1" title="Interest expense, debt, excluding amortization">77,700 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the three and six months ended June 30, 2026. Pacific Pier June 2026 Financing On June 23, 2026, the Company entered into the 2026 Pacific Pier SPA with Pacific Pier, whereby the Company issued the 2026 Pacific Pier Note in the aggregate principal amount of $178,410 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Pacific Pier has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at the lesser of a fixed rate of $0.06 or <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260623__srt--TitleOfIndividualAxis__custom--JuneTwentyTwentySixFinancingtNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z76lHVRZDtkg">85% of the lowest traded price of the Common Stock on the Principal Market on any Trading Day during the ten (10) Trading Days prior to the respective Conversion Date. The Company also issued 500,000 of the Company’s common stock as commitment shares to Pacific Pier. <div id="xdx_C04_gL3SODTTB-TUXY_zZ6Er8HAqtqj">The 2026 Pacific Pier convertible note, net of debt discounts, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_309_134_zDhjAEGfH2ok" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF NET OF DEBT DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260630__srt--TitleOfIndividualAxis__custom--JuneTwentyTwentySixFinancingtNoteMember_z5C9ZciBfH8k" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__srt--TitleOfIndividualAxis__custom--JuneTwentyTwentySixFinancingtNoteMember_zI3VvhR1N2mj" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TwelvePercentCouponJuneTwoThousandTwentySixMember_zFwNPDuU8Kcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Pacific Pier Convertible note, inclusive of accrued interest 12% coupon, gross</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">178,821</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zvgYI8mO5B3d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(50,336</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zxN8ZVV8l33j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">965</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zRFUuKEgTIGg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Pacific Pier 2016 convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The Company recognized approximately $410 of accrued interest during the three and six months ended June 30, 2026. There was no similar expense during the same periods in 2025. The Company recognized approximately $1,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the three and six months ended June 30, 2026. On August 3, 2026, the Company and Pacific Pier entered into a new note with the exact same terms as the 2026 Pacific Pier SPA and 2026 Pacific Pier Note Refer to our subsequent event disclosure in note 16. Other short-term advances Other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Other Advances</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20260630__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zkWZe6roossh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zzJsI1QnyiO5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zacr9XDxz7df" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%">Short-term advance from CFO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">86,050</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">86,050</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zdhFUKJMBuL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advances – bridge investors & others</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_z8ixcqMkcGFk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advances – Autotelic Inc. – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,067,801</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,992,874</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerRelatedPartyMember_zQMJUTaRMzrd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advance – CEO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">175,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zfy7JWvPsVy3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advance – Accredited investor</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zMsiDOnXysXf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short term advance </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,538,851</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,513,924</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> As of January 1, 2025, approximately $2 million was outstanding and payable to Autotelic. During the year ended December 31, 2025 Autotelic Inc. provided additional short-term funding of approximately $1.0 million to the Company. During the six months ended June 30, 2026 Autotelic Inc. provided additional short-term funding of $75,000 to the Company. As such, approximately $3.1 million was outstanding and payable to Autotelic at June 30, 2026. As of January 1, 2025, approximately $76,000 was outstanding and payable to the Company’s CFO. During the year ended December 31, 2025, the CFO provided additional short-term funding of $10,000. As such, approximately $86,000 was outstanding and payable to the Company’s CFO at June 30, 2026. In December 2023, the Company received $50,000 from the Company’s CEO. In December 2025, the amount due from PPM-2 payable to the CEO of $125,000 was converted into a short-term loan. As such, $175,000 was outstanding to the Company’s CEO at June 30, 2026. As of June 30, 2026, approximately $210,000 was outstanding as short-term advances from certain bridge investors.

As of June 30, 2026, and December 31, 2025, special purchase agreements (“SPAs”) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_zT65nVLnhiLc" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_z21GNaiIUJgk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zcTG2MJiRyla" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zGlulO3DPMtg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zI1g9JaTs6Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zbn4XOHXckck" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zsjb08RWnIU1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">138,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z11xXIOJ94Z" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">326,233</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zRWhbya5DYF1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zSolYGwbhzh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,759</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zh2vRJyhhBb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">222,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">218,722</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zT6gBuGMEeHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,137,675</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,116,425</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_z17T3XYT6iPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,052</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zM2sApQksNy" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,751</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zdKjOH3AGB95" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">93,398</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91,522</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zptCte34Dm8b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">869,789</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">852,325</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zQ2RM91XRyv2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">61,480</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,531</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Debt for Clinical Trials – Forever Prosperity ( Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zBqCoOBca5kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,974,877</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,930,247</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">May 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_z3ZjmalpPHub" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">809,492</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">J.H. Darbie PPM-2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--AccruedAndUnpaidInterestMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zEmJKTVsXz5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued and Unpaid Interest – PPM-2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,111</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">102,795</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">July 2025 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyFiveNoteMember_zk61aBzomuQf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">595,179</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">465,261</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">January 2026 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoThousandTwentySixNoteMember_zqNx7fmwuq8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note - Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">314,153</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Pacific Pier 2026 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--PacificPierTwoThousandTwentySixNoteMember_zip3Jj50rxDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">12% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">129,450</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Other Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z3VefZl2bmF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z0kGAx7Aspn3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zWchVUpsTbH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,067,801</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,992,874</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zqIsZcPAkuM" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term Debt from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAccreditedInvestorMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z39axcxQW5ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short-term loan from Accredited investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zhB0uhrxa5Zj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,538,851</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,513,924</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleDebtCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_ziX2aXfksD89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible and short-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,925,881</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,225,669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNvVDUpG2xAi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible debt and short-term debt – related party, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,114,684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,023,331</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260630_z8Vs0k6kHej1" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zs1gwdtlAK59" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; width: 60%; font-weight: bold; text-align: left">Long Term Debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">12% convertible note - JH Darbie PPM-3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM3DebtMember_zj00NYIJBqQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--TwelvePercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM3DebtMember_zfcJJP0UgP9i" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Convertible Note payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

35556

164444

200000

400000

141458

138958

332483

326233

332003

325753

108809

106759

222922

218722

1137675

1116425

311302

305052

465089

455751

93398

91522

869789

852325

61480

58531

4974877

4930247

809492

19111

102795

595179

465261

314153

129450

210000

86050

3067801

2992874

175000

50000

3538851

3513924

7925881

8225669

4114684

4023331

1854395

1663405

1854395

1663405

337200

12800

350000

353600

400000

500000

1000000

250000

500000

250000

35000

27000

20000

168000

0.05

850000 850000

10625

21250

2000000

0.02

1500000

0.02

500000

0.02

5000000.0

4900000

22000

44600

698500

691000

The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18.

0.18

<p id="xdx_898_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-VWTYID_zO2VfJcJW234" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The August 2021 convertible notes, inclusive of accrued interest, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zTe6t1vuP074" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_z54X0F9bntYh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zuFTuFEF0lg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Autotelic - Related party convertible note, 5% coupon December 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">311,302</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">305,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zw2Rp1mHt5Eg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CFO - Related party convertible note, 5% coupon December 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zMNTDwT8q9X8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accredited investors convertible note, 5% coupon December 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">465,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">455,751</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zev9mMGF4D0g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total August 2021 convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">869,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">852,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The March 2022 Fourth Man convertible note, including accrued interest and net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zzJtwrlEJeR9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260630__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zB2tCiVz94Kh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_znbm5OfuiLbl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zhybGRdwW54b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61,480</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,531</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_hus-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zSVnM43fGtm3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zDvighxiVdF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">61,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">58,531</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The May 2022 Mast Financing, net of debt discount, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_307_134_zLFNdWhCkpta" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zKrXsMdClI4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zeXzIZyXkC47" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_hdei--LegalEntityAxis__custom--MastHillMember__us-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_zroIwWtQ3pG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">809,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--MayTwoThousandTwentyTwoNoteMember_zN0IWxmoXcs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total May 2022 convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">809,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

311302

305052

93398

91522

465089

455751

869789

852325

8700

17500

4000

8100

200000

250000

0.12

0.16

0.10

0.07

1250000

0.20

125000

0.20

61480

58531

61480

58531

150000

54100

2991270

1.25 70000

300000

2500

5000

8200

15400

605000

0.12

0.16

0.10

3025000

0.20

302500

272000

3860000

82000

847000

11877507

809492

560000

0.12

0.18

0.07

2000000

0.15

2250000

0.45

The July 2025 Mast Note, net of debt discount, consists of the following amounts: SCHEDULE OF NET OF DEBT DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20260630__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zsx7vn1tV7he" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20251231__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_znyeWN9ORITj" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponAugustTwoThousandTwentySixMember_zYyOG0GWBoOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Mast Hill Convertible note, inclusive of accrued interest 12% coupon due January 2027, gross</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">611,511</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">583,512</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zucl2GE2y5Wg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Less: debt discount recorded</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(203,833</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(203,833</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zvCFMog0M5C5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Amortization of debt discount</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">187,501</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">85,582</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zrAlwSvZg4F4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible notes, net</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">595,179</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">465,261</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> The convertible note under the 2026 Mast Note, net of debt discount, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30D_134_zbkX9BwrTEcg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF NET OF DEBT DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260630__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zaLkPl2JrkY4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231__srt--TitleOfIndividualAxis__custom--JanuaryTwoThousandAndTwentySixMastNoteMember_zaNSWNO1v3ee" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponJanuaryTwoThousandTwentySevenMember_zqAudzE0OwY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, inclusive of accrued interest 10% coupon January 2027, gross</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">415,603</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zm7hIqJtBX8j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(179,102</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zFotLHSeTzfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">77,652</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zhJrlDr4MSg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">314,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The 2026 Pacific Pier convertible note, net of debt discounts, consists of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_309_134_zDhjAEGfH2ok" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF NET OF DEBT DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260630__srt--TitleOfIndividualAxis__custom--JuneTwentyTwentySixFinancingtNoteMember_z5C9ZciBfH8k" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__srt--TitleOfIndividualAxis__custom--JuneTwentyTwentySixFinancingtNoteMember_zI3VvhR1N2mj" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TwelvePercentCouponJuneTwoThousandTwentySixMember_zFwNPDuU8Kcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Pacific Pier Convertible note, inclusive of accrued interest 12% coupon, gross</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">178,821</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zvgYI8mO5B3d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(50,336</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zxN8ZVV8l33j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Amortization debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">965</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zRFUuKEgTIGg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Pacific Pier 2016 convertible note, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

611511

583512

203833

187501 85582 595179 465261

14000

28000

51000

102000

398333

0.10

0.18

0.07

1422613

0.15

1600446

415603

179102

77652 314153

7300

17000

32900

77700

178410

0.12

0.16

0.06

0.85

500000

178821

50336

965 129450

410

1000

Other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Other Advances</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20260630__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zkWZe6roossh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zzJsI1QnyiO5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zacr9XDxz7df" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%">Short-term advance from CFO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">86,050</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">86,050</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zdhFUKJMBuL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advances – bridge investors & others</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_z8ixcqMkcGFk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advances – Autotelic Inc. – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,067,801</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,992,874</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerRelatedPartyMember_zQMJUTaRMzrd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advance – CEO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">175,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zfy7JWvPsVy3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Short-term advance – Accredited investor</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zMsiDOnXysXf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Short term advance </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,538,851</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,513,924</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

86050

210000

3067801

2992874

175000

125000

50000

3538851

3513924

2000000

1000000.0

75000

3100000

76000

10000

86000

50000

125000

175000

210000

NOTE 6 – JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT On March 31, 2022, the Company entered into (i) an agreement to form the JV with Dragon, GMP Bio, both affiliates of GMP, (ii) a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the Company received a <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JVMember_zAVrQYZEWYRi" title="Ownership percentage">45% ownership interest in the JV. The combined enterprise value of GMP Bio was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million. The JV was initially funded by equity contributions from Dragon under the terms of the joint venture agreement. That equity funding commitment has been fully paid as of June 30, 2025. In May 2025, GMP Bio and Golden Mountain Partners, an affiliate of Dragon, entered into a note purchase agreement and promissory note pursuant to which Golden Mountain Partners agreed to loan funds to the JV sufficient to meet its operating expenses for 2025 and beyond. The loans are made as monthly advances, bear interest at the Wall Street Journal “Prime” rate, and mature on December 31, 2026. Amounts due under the promissory note are convertible into equity of the JV at the election of Golden Mountain Partners at a price equal to 80% of the price for shares issued in connection with an equity financing of $20 million or more, or otherwise at a mutually agreed price. As of June 30, 2026, the JV had approximately $26.1 million in assets, recorded approximately $20 million in liabilities, including loans of approximately $15.3 million, and incurred approximately $8.6 million and $6.4 million in operational expenses for the six months ended June 30, 2026 and June 30, 2025, respectively. The JV has initiated phase 2 and 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer. In late 2023, the JV initiated a plan to start evaluating various nanoparticles that could treat various cancers. In this regard, the JV identified a total of 4 compounds, in addition to OT-101, which had the potential of significant revenue generation for the JV. In the same year, the JV signed a lease agreement to set up a GMP manufacturing facility in San Diego (“SD”), California. The main purpose of this facility was to initially commence an aggressive formulation development of newly planned nanoparticle platform (“Nano Platform”). The GMP manufacturing facility was initiated in January 2024. Upon the initiation of this facility by the JV, the JV commenced the development work on two of the four identified compounds, as well as other activities, in tandem with the development of OT-101. The JV has since completed the formulation development of one of the products and is moving to complete the formulation development for the three additional products. The JV is also working on improved formulations for OT-101 with new nanoparticle sizes. The JV also has started clinical development for OT-101 for pancreatic cancer. Significant progress has been made in the development of the products and the JV anticipates to complete the formulation development work in 2026 and pushing to initiate clinical trials for the various compounds. In late 2024, the GMP facility in San Diego was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. Further, in late 2024, the JV identified a sixth candidate as a compound for development for the JV and has already started to work on the formulation development of that compound as well. All developmental and manufacturing, including for Phase 1 clinical trial materials, will be performed at the SD site. In early 2025, the Company announced that it had entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid investigational new drug (“IND”) development platform to support up to 20 IND projects, which the JV can also utilize to support their INDS. All six of our compounds the JV is developing are planned to be these INDs and are focused on becoming next-generation anticancer agents. The JV anticipates that all these six anticancer agents have the potential to become significant growth contributors to the JV, which in turn would add substantial value to the Company. The Company successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The Company elected the fair value option under subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that it the most appropriate method to properly value the Company and record a change in value when and upon conducting a fair value assessment. As of December 31, 2025, as the development and IPO operations of the JV are proceeding as planned, the Company assessed the fair value of its investment in the JV. The Company also utilized the services of an ASC-compliant third party valuation firm to validate the Company’s assessment. Based on the Company’s assessment and report, and considering the Company’s <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_zbc1kVUtPED5">45% ownership in the JV, the Company proceeded to record an increase in fair value of the Company’s ownership interest in GMP Bio of approximately $<span id="xdx_906_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GMPBiotechnologyLimitedMember_z6vFqJj5FUSf" title="Investment owned">365.4 million. As the circumstances related to the JV have not materially changed since December 31, 2025, the Company assessed and determined that no additional fair value adjustment was required during the three and six months ended June 30, 2026, and hence, the Company has not recorded a change in value of the Company’s interest in the JV. <p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_zC8n3nUMiy9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the change in the fair value of our investment in GMP Bio, is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iS_c20260101__20260630_zYavloCDMZx5" style="width: 16%; text-align: right" title="Balance at beginning of period">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iS_c20250101__20251231_zt8LS6M7ODs7" style="width: 16%; text-align: right" title="Balance at beginning of period">22,653,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--GainLossOnInvestments_c20260101__20260630_zoBRfYw9fk0c" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_c20250101__20251231_zxxSZcG9jSTg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">365,346,775</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iE_c20260101__20260630_zICl0X4Z2OT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iE_c20250101__20251231_zqrj4UfJi0z" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For detailed and more information on the fair value of our investment in GMP Bio, refer to Note 2 to the unaudited Condensed Consolidated Financial Statements: Change in Fair Value of Equity Securities of GMP Bio.

0.45

50400000

22700000

27700000

20000000

26100000

20000000

15300000

8600000

6400000

0.45

365400000

<p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_zC8n3nUMiy9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the change in the fair value of our investment in GMP Bio, is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iS_c20260101__20260630_zYavloCDMZx5" style="width: 16%; text-align: right" title="Balance at beginning of period">388,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iS_c20250101__20251231_zt8LS6M7ODs7" style="width: 16%; text-align: right" title="Balance at beginning of period">22,653,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--GainLossOnInvestments_c20260101__20260630_zoBRfYw9fk0c" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_c20250101__20251231_zxxSZcG9jSTg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">365,346,775</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iE_c20260101__20260630_zICl0X4Z2OT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iE_c20250101__20251231_zqrj4UfJi0z" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">388,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

388000000

22653225

365346775

388000000

NOTE 7 - PRIVATE PLACEMENT -2 (PPM-2) AND JH DARBIE FUNDING During the period between July 2023 to January 2024, the Company entered into a series of subscription agreements with forty-six accredited investors, whereby the Company issued and converted a total of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zMLHsmpAb0C6" title="Sale of transaction shares">94 Units from a previous offering, which resulted in conversion of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zyPy9PQQckha" title="Short term debt">2.35 million of old debt into new debt to the Company (the “PPM-2 Financing”). The Company did not receive any cash proceeds through the PPM-2 Financing. Each of the new units under the PPM-2 Financing consisted of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">One <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zoszNRTCjEF8" title="Percentage of convertible unsecured promissory note">16% convertible unsecured promissory note (the “Note”) of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zScvOpHwRugk" title="Shares and warrants issued in connection with debt, shares">25,000, convertible into up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_ztYBR94K6DFb">250,000 shares of the Company’s common stock (par value of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zRxvXG91zN28">0.01) based on a conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zSe5p7gZLEki" title="Conversion price">0.10 per share, subject to standard anti-dilution protection.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKAg7zZ08phf" title="Number of common stock issued">250,000 warrants to purchase an equivalent number of shares of the Company’s common stock at a strike price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKT0F1GAy3l8" title="Shares issued price per share">0.12 per share.</td></tr> </table> In December 2025, the Company converted the debt of forty-seven accredited investors from PPM-2 into the new subscription agreements under the new financing (“PPM-3”- See Note 8 below) in three tranches, which resulted in conversion of approximately $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember_zK7rN7mNWaz6" title="Short term debt">2.2 million of the PPM-2 debt into the PPM-3 debt. Two PPM-2 investors did not participate in the PPM-3 financing and as such, their <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20251231__20251231__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zpbCkdIJnN04" title="Sale of transaction shares">7 units for a total of approximately $<span id="xdx_906_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zuLcLynDiJ8h" title="Converted debt">0.2 million was converted into short term loan to the Company. As of June 30, 2026, PPM 2 financing only consists of the returned and unpaid accrued interest and no principal. The short term loan of one of the investors was repaid, including accrued interest, during the six months ended June 30, 2026. <p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_z97Nh6QVIWXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The PPM2 - JH Darbie Financing, net of debt discounts, consisted of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260630_zldizCnVivj5" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231_zQsSCHCoinf4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepositLiabilitiesAccruedInterest_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQiVVCfKpchd" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Accrued, returned and unpaid interest</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">19,111</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">102,795</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_zKD4lcmCLHvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total PPM-2 Darbie Financing, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2025, the Company reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt- Modifications and Extinguishments and concluded that the terms of the agreements were substantially different and accounted for the transaction as a debt extinguishment. The transaction related to the debt extinguishment during the year ended December 31, 2024 resulted in a loss from debt extinguishment of approximately $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zwWkbcdbTR3c" title="Extinguishment of debt amount">88,000, with a corresponding increase to additional paid-in capital. All warrants sold in this offering had an exercise price of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkOPgRqJYa88" title="Share price">0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values: <p id="xdx_89B_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_hus-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zXbdwMmh9g4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected Term</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zTALxglZL92b" title="Warrant expected term">2 years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zwLF5MOk8At5" title="Warrants measurement input">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zoxY99r6zGnc" title="Warrants measurement input">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zSUr6OM0D3x9" title="Warrants measurement input">0.00</td><td style="text-align: left">%</td></tr> </table> The Company recorded approximately $318,000 as an initial debt discount related to the four tranches of PPM 2. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $0 and $78,000 for the six months ended June 30, 2026 and 2025, respectively, which is included in interest expense in the statements of operations. During the six months ended years ended June 30, 2026 and 2025, the Company incurred approximately $<span id="xdx_906_eus-gaap--InterestExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcAWoPGdFiz9" title="Interest expense">0 and $<span id="xdx_90B_eus-gaap--InterestExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrCS0vUZ1A7k" title="Interest expense">176,000 of interest expense related to the convertible notes.

2350000

0.16

25000

250000

0.01

0.10

250000

0.12

2200000

200000

<p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_z97Nh6QVIWXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The PPM2 - JH Darbie Financing, net of debt discounts, consisted of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260630_zldizCnVivj5" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231_zQsSCHCoinf4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepositLiabilitiesAccruedInterest_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQiVVCfKpchd" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Accrued, returned and unpaid interest</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">19,111</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">102,795</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_zKD4lcmCLHvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total PPM-2 Darbie Financing, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

19111

102795

19111

102795

88000

0.12

<p id="xdx_89B_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_hus-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zXbdwMmh9g4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected Term</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zTALxglZL92b" title="Warrant expected term">2 years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zwLF5MOk8At5" title="Warrants measurement input">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zoxY99r6zGnc" title="Warrants measurement input">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember_zSUr6OM0D3x9" title="Warrants measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

P2Y

173

4.29

0.00

318000

78000

176000

NOTE 8 – PRIVATE PLACEMENT -3 (“PPM-3”) AND JH DARBIE FUNDING In December 2025, the Company entered into a series of subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and converted a total of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z1JlO8DRsMO3" title="Sale of transaction shares">87 Units from the previous PPM-2, into the current subscription agreements under the PPM-3, which resulted in conversion of approximately $<span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zSy196ig1nZ" title="Short term debt">2.2 million of the PPM-2 to PPM-3 the Company did not receive any cash proceeds through the December 2025 conversions, with each Unit consisting of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">One <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zwMXbFgtdxma" title="Percentage of convertible unsecured promissory note">12% unsecured convertible promissory note (the “Note”) of principal amount of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zoIuPfCkq2F6" title="Number of common stock value">25,000 and convertible into up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zGAUk6hHGPFj" title="Number of common stock shares">250,000 shares of the Company’s common stock (par value of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zJZ7s0Ee20Pb" title="Share price">0.01) based on a conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zDpAcYX4MTqj" title="Conversion price">0.10 per share.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251201__20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKE5uIhogFF3" title="Number of common stock issued">250,000 warrants to purchase an equivalent number of shares of the Company’s common stock at a strike price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTr8MiEHUHll" title="Shares issued price per share">0.12 per share (“Oncotelic warrant”) with a contractual term of two years.</td></tr> </table> In December 2025, in a series of three tranches, the Company converted the debt of forty-seven (47) accredited investors from PPM-2 (See Note 7 above) into the current subscription agreements under the PPM-3, which resulted in conversion of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMThreeDebtMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zgUYyVOon9jc">2,175,000 of old debt into new debt to the Company. The Company did not receive any cash proceeds through the conversions. JH Darbie and the Company are parties to a May 2024 placement agent agreement (“Agreement”) pursuant to which JH Darbie had the right to sell a minimum of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zm7MrZ0HbQV8">10 Units and a maximum of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zG0LEeXDTpvg">200 Units on a best-efforts basis. Initial placement agent fees of $25,000 were paid to JH Darbie in June 2024. Subsequently, the Company paid JH Darbie an amount of $326,250 for processing the three tranches of the Financing. Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company is to provide warrant coverage equal to 10 % of all of the units sold to JH Darbie. As the Company converted an aggregate of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp0p0_c20251201__20251231__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember__us-gaap--TypeOfArrangementAxis__custom--AccreditedInvestorsMember_zeiobOqURLB9">87 units, JH Darbie was entitled to earn a total of <span id="xdx_903_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20251231__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember_zNPi67LbQne3">2,175,000 warrants. A total of 2 investors holding <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20251231__20251231__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zeMFkw11AReh">7 units under the PPM-2 opted not to participate in the PPM-3 and approximately $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zeM8kYEVaVr6">0.2 million of notes were converted into short-term loan to the Company. Subsequently, one of the investors was repaid his loan of $<span id="xdx_908_eus-gaap--DebtInstrumentRepaidPrincipal_pp0p0_c20260101__20260630__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMThreeDebtMember__us-gaap--TypeOfArrangementAxis__custom--NewSubscriptionAgreementsMember_zTs17IfVznX9" title="Debt instrument repaid">50,000, including accrued interest, before the filing of this Report. In connection with the consummation of the PPM-3 financing, the Company entered into Registration Rights Agreements granting certain registration rights with respect to the shares of the Company’s Common Stock issued in connection with the financing, as well as the shares of the Company’s Common Stock issuable upon exercise of the Warrants. The issuance of the Units is exempt from the registration requirements of the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of common stock and warrants and any shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. <p id="xdx_89D_ecustom--ScheduleOfDebtRecordedUnderTheSubscriptionAgreemenDebtDiscountTableTextBlock_zUDWGS1kSRv" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The December 2025 JH Darbie Financing, net of debt discounts, consists of the following amounts: SCHEDULE OF DEBT RECORDED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260630_zSkYPAAAhgfb" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231_zqVcKkp6jkn5" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zICX5ORZJ9rk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Subscription agreements - accredited investors</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,854,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,663,405</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zN70eAsnbnMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total convertible promissory, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company incurred approximately $0.3 million of issuance costs, consisting of incremental costs related to the issuance of the various instruments bundled in the offering. Concurrently with the sale of the Units, JH Darbie was granted a total of <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesWarrantsGranted_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zYhJbK6pJ7V9" title="Stock issued during the period warrant grant">2,175,000 stock warrants, exercisable over a two-year period. The terms of convertible notes are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Term: through December 31, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Coupon: <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zqRnG4zKPfn9" title="Percentage of convertible unsecured promissory note">12%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible at the option of the holder at any time into the Company’s common stock</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Conversion price is set at $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zZaeVZ6fEQ06" title="Conversion price">0.10 per share subject to standard anti-dilution provision.</td></tr> </table> Management reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments and concluded that the terms of the agreements were substantially different and accounted for the transaction as a debt extinguishment. The transaction resulted in a loss from debt extinguishment of approximately $1.2M, which is presented in other expense in the condensed consolidated statements of operations for the year ended December 31, 2025. The estimated volume weighted grant date fair value of approximately $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF0FLbnkvb09" title="Conversion price">0.053 per share associated with the warrants to purchase up to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7MrXt6KYe8e" title="Share based compensation arrangements, grants">21,750,000 shares of common stock issued in this offering, or a total of approximately $<span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_pn5n6_c20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3tK0aJc8Ze" title="Additional paid in capital">1.2M, was recorded to additional paid-in capital. All warrants sold in this offering have an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z65i1mFOdBej" title="Share price">0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values: <p id="xdx_895_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_hus-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zbj2D72TbMj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zXz07BQ3XXd8" title="Warrant expected term">2 years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; text-align: justify">Expected volatility</td><td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zGAiDH0LKWI7" title="Warrants measurement input">127.9% - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zlZw5B1NShPa" title="Warrants measurement input">132.2</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zZ0p9qbeuE89" title="Warrants measurement input">3.47% - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zNahDzVQnsb4" title="Warrants measurement input">3.52</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: justify">Dividend</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zKb4ZRNnpOW8" title="Warrants measurement input">0.00</td><td style="width: 1%; text-align: left">%</td></tr> </table> The Company recorded an initial debt discount of approximately $511,600 for the year ended December 31, 2025. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $<span id="xdx_90B_eus-gaap--AmortizationOfFinancingCosts_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_z5qfxUYUPFsh" title="Debt discount and issuance costs">121,500 and $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zl8n5l5i0XU8" title="Debt discount and issuance costs">0 for the six months ended June 30, 2026 and 2025, respectively, which is included in interest expense in the statements of operations. During the three and six months ended June 30, 2026, the Company incurred approximately $<span id="xdx_908_eus-gaap--InterestExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zuFViOntOEDk" title="Interest expense">64,000 and $<span id="xdx_905_eus-gaap--InterestExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zJqD8RSxrf62" title="Interest expense">129,000 of interest expense related to the convertible notes. There was no similar expense during the same period in 2025.

2200000

0.12

25000

250000

0.01

0.10

250000

0.12

2175000

200

25000

326250

Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company is to provide warrant coverage equal to 10 % of all of the units sold to JH Darbie. As the Company converted an aggregate of 87 units, JH Darbie was entitled to earn a total of 2,175,000 warrants.

2175000

200000

50000

<p id="xdx_89D_ecustom--ScheduleOfDebtRecordedUnderTheSubscriptionAgreemenDebtDiscountTableTextBlock_zUDWGS1kSRv" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The December 2025 JH Darbie Financing, net of debt discounts, consists of the following amounts: SCHEDULE OF DEBT RECORDED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260630_zSkYPAAAhgfb" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231_zqVcKkp6jkn5" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zICX5ORZJ9rk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Subscription agreements - accredited investors</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,854,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,663,405</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--JHDarbiePPMThreeDebtMember_zN70eAsnbnMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total convertible promissory, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,854,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,663,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1854395

1663405

1854395

1663405

300000

2175000

0.12

0.10

1200000

0.053

21750000

1200000

0.12

<p id="xdx_895_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_hus-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zbj2D72TbMj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zXz07BQ3XXd8" title="Warrant expected term">2 years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; text-align: justify">Expected volatility</td><td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zGAiDH0LKWI7" title="Warrants measurement input">127.9% - <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zlZw5B1NShPa" title="Warrants measurement input">132.2</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zZ0p9qbeuE89" title="Warrants measurement input">3.47% - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zNahDzVQnsb4" title="Warrants measurement input">3.52</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: justify">Dividend</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbieSubscriptionAgreementMember_zKb4ZRNnpOW8" title="Warrants measurement input">0.00</td><td style="width: 1%; text-align: left">%</td></tr> </table>

P2Y

127.9

132.2

3.47

3.52

0.00

511600

121500

64000

129000

NOTE 9. LUNAI BIOWORKS TRANSACTIONS Intellectual Property Development and Services Agreement with Lunai Bioworks, Inc. On April 17, 2026, the Company and Lunai Bioworks, Inc., a Delaware corporation (“Lunai”) entered into an intellectual property development and services agreement (“IP Services Agreement”), whereby the Company was to perform intellectual property development and business development services relating to a Nose-to-Brain (“N2B”) delivery platform. This includes applications in biodefense, Alzheimer’s disease (“AD”), and broader central nervous system (“CNS”) indications and excludes Parkinson’s disease and sexual dysfunction. The work shall focus on direct-to-CNS delivery to bypass the blood-brain barrier. The scope of services included scientific development, IP execution, technical data delivery, business development support and broadened biodefense focus. In connection with these services, Lunai agreed to compensate the Company a total compensation of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20260417__20260417__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__dei--LegalEntityAxis__custom--LunaiBioworksIncMember_zBWpmKJepb12" title="Share based compensation">250,000, of which $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20260417__20260417__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__dei--LegalEntityAxis__custom--LunaiBioworksIncMember_z79TI59OpHMj" title="Account payable related party">62,500 was payable upon signing of the IP Services Agreement, $<span id="xdx_909_ecustom--ProvisionalPatentsAmount_c20260417__20260417__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__dei--LegalEntityAxis__custom--LunaiBioworksIncMember_zovA8pZBy3T6" title="Provisional patents amount">62,500 upon filing of provisional patents and $<span id="xdx_906_eus-gaap--RepaymentsOfRelatedPartyDebt_c20260417__20260417__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__dei--LegalEntityAxis__custom--LunaiBioworksIncMember_zNzLfsEBQ8E7" title="Account payable">125,000 payable upon the execution of a biodefense and neurodegenerative platform IP acquisition agreement by Lunai, which was the agreement and plan for merger with Lunai, described below. The Company has completed all its obligations under the IP Services Agreement, invoiced Lunai for the services and recognized the revenue under the IP Services Agreement during the three and six months ended June 30, 2026 for an aggregate amount of $250,000, which was recorded as service revenue in the unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2026. No similar services revenue were recorded in the three and six months ended June 30, 2025. Agreement and Plan of Merger with Lunai On April 27, 2026, Oncotelic Inc., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lunai, Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), and the holders of all of the issued and outstanding capital stock of Holdings, namely Oncotelic Inc. and Pelerin Therapeutics Inc., a corporation existing under the laws of the Province of British Columbia, Canada (“Pelerin” and, together with Oncotelic Inc., the “Holders”). Pursuant to the Merger Agreement, Holdings merged with and into Merger Sub in a triangular merger (the “Merger”), with Merger Sub continuing as the surviving corporation and as a wholly owned subsidiary of Lunai. The Merger was completed on May 1, 2026. Immediately prior to the effective time of the Merger, all of the issued and outstanding capital stock of Holdings was owned <span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20260426__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--OwnershipAxis__custom--LunaiBioworksIncMember_zJavJAvmtN92" title="Ownership percentage">62.5% by Oncotelic Inc. and <span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20260426__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--OwnershipAxis__custom--LunaiBioworksIncMember_za4I7dDlS1Tl" title="Minority interest percentage">37.5% by Pelerin. The sole assets of Holdings at the effective time of the Merger consisted of a multi-jurisdictional patent portfolio (collectively, and as further defined in the Merger Agreement, the “Patents”), which the Holders had contributed to Holdings prior to the effective time. In consideration for the Merger, on May 1, 2026 Lunai issued to the Holders an aggregate of eight (<span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20260501__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z7dpTMBWIq7d" title="Shares issued">8) shares of a newly designated series of preferred stock of Lunai, designated as “Series B Convertible Preferred Stock” (the “Series B Preferred Stock”), having an aggregate stated value (the “Stated Value”) of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20260501__20260501__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z3139XLZLTkd" title="Shares issued values">20,000,000. The Series B Preferred Stock was allocated five (<span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20260501__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4qfCiN2tXua" title="Shares issued">5) shares to Oncotelic Inc. (representing <span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20260501__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znDRaIBGaZI4" title="Ownership percentage">62.5% of the Series B Preferred Stock and an aggregate Stated Value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20260501__20260501__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoNMtdCS8b49" title="Shares issued values">12,500,000). For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026. IP Assignment Agreement In connection with the Merger Agreement, on April 27, 2026, Oncotelic Inc. entered into an IP Assignment Agreement with Holdings, pursuant to which it agreed to contribute and assign certain assets relating to the intellectual property of the Company (collectively, the “Intellectual Property Assets”) to Holdings. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026. IP Grant-back Agreement Further, on April 27, 2026, the Company and Holdings entered into an Intellectual Property Assignment and Grant-back Agreement (the “IP Grant-back Agreement”). The IP Grant-back Agreement grants back to the Company a perpetual, irrevocable, royalty-free, exclusive, non-terminable, and non-cancellable license to make, have made, use, offer to sell, sell, and otherwise exploit the Intellectual Property Assets in all fields of use except the Biodefense Field and the Alzheimer’s Disease Field as defined in the IP Grant-back Agreement, giving Holdings exclusive use of the Intellectual Property Assets in those fields. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026. Asset Transfer Agreement Further, on April 30, 2026, Oncotelic Inc. on behalf of the Company, and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”) pursuant to which Autotelic agreed to transfer all the rights, title and interest to certain assets (“Assets”), described below and owned by Autotelic to Oncotelic Inc. This Asset Transfer Agreement was entered into by both parties to effectuate the Merger Agreement. Dr. Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc., is a partial owner and control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The Assets transferred pursuant to the Asset Transfer Agreement include Peptide Y (including all variants, analogs, derivatives); Parathyroid Hormone (“PTH”), including PTH 1-34, PTH 1-84, and derivatives; Insulin (including intranasal and other formulations); Apomorphine (including intranasal and other formulations); Carbetocin (including intranasal and other formulations); any associated combination therapies, including multi-agent CNS, AD, metabolic, endocrine, or biodefense applications; and all delivery platforms, including nasal, injectable, and device-based systems and includes all patents, patent applications, know-how, trade secrets, data, formulations, manufacturing processes, regulatory filings, and all related rights associated with the Assets. In consideration for the transfer of the Assets, the Company shall issue equity of ten percent (<span id="xdx_903_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20260430__us-gaap--TypeOfArrangementAxis__custom--AssetTransferAgreementMember__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7W8ZzWT3k41" title="Ownership percentage">10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NYSE/NASDAQ. No cash was paid for the Asset Transfer Agreement. The consideration payable to Autotelic is contingent on the Company uplisting its Common Stock to a nationally recognized stock exchange. Such shares of the Company have not been issued to Autotelic as of the date of this filing and are not legally due to be issued until the uplisting of the Company’s stock onto a nationally recognized stock exchange. If the uplisting does not occur, then the shares would not be issuable, and neither would the transaction with Lunai be invalidated. Even though the Company received the Series B Preferred Stock from Lunai with a stated value of $<span id="xdx_909_eus-gaap--LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue_iI_pn5n6_c20260630__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCNjGAZGP827">12.5 million, the Company initially recorded $<span id="xdx_908_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20260630__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziTQAk6d8Yi2">1.1 million as a fair value for its investment in Lunai upon the exchange of the Company’s non-financial asset, which had zero carrying basis. At June 30, 2026, the Company increased the fair value of its equity investment by an additional $<span id="xdx_902_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20260101__20260630__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zu5EBiXbP2wg" title="Gain in the value"><span id="xdx_900_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20250101__20250630__srt--OwnershipAxis__custom--LunaiBioworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuVHIZpYpxib" title="Gain in the value">0.3 million, which is presented in change in fair value equity investment in the Company’s unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2026. Such increase was attributable to the increase in the market capitalization of Lunai. For more information on the fair value of the investment in Lunai, refer to Fair Value Hierarchy – Lunai above.

250000

62500

125000

250000

0.625

0.375

20000000

0.625

12500000

0.10

12500000

1100000

300000

NOTE 10 - RELATED PARTY TRANSACTIONS Master Service Agreement with Autotelic Inc. In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is partly owned by the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. Expenses related to the MSA were approximately $<span id="xdx_909_eus-gaap--OperatingCostsAndExpenses_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQDpPRzE7qp5" title="Related party expenses"><span id="xdx_90C_eus-gaap--OperatingCostsAndExpenses_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjwecZ45wcH5" title="Related party expenses">500 and $<span id="xdx_90B_eus-gaap--OperatingCostsAndExpenses_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIQyp7Ft5lva" title="Related party expenses"><span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zgyLIU3Ng0Ea" title="Related party expenses">1,000 for the three and six months ended June 30, 2026 and 2025, respectively. License Agreement with Autotelic Inc. In September 2021, the Company entered into an exclusive License Agreement with Autotelic. For more information on the exclusive license Agreement with Autotelic, refer to our 2025 Annual Report on Form 10-K filed with SEC on April 15, 2026. Notes Payable and Short-Term Loan – Related Parties In April 2019, the Company issued a convertible note to Dr. Trieu totaling $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zAYft3dz29Y1" title="Debt instrument face amount">164,444, including OID of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNt2YQAcArd" title="Debt instrument unamortized discount">16,444, receiving net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromConvertibleDebt_c20190401__20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZgAICAl6iH8" title="Proceeds from convertible debt">148,000, which was used by the Company for working capital and general corporate purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ze2eYbMi4yi3" title="Debt instrument face amount">250,000. Dr. Trieu also offset certain amounts due to him in the amount of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190401__20190430__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandAndNineteenNoteMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_z3wvnoIgu2Ni" title="Debt conversion">35,000 and was converted into the Fall 2019 debt. As of January 1, 2025, Dr Trieu had provided a short-term loan of $50,000 to the Company. During the year ended December 31, 2025, Dr. Trieu converted his holding in PPM-2 of $125,000 into a short-term loan with the Company. As such, the balance due and payable to Dr. Trieu, as of June 30, 2026, and December 31, 2025, was $175,000. In November 2025, the Company entered into a restricted stock agreement (the “RSA-1”) with Dr. Trieu, to provide incentive compensation for his extra-ordinary efforts and time to raise capital and successful achievement of certain milestones. The RSA-1 provides for a grant of up to <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20251101__20251130__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zhFetnm3WXK9">24,387,516 shares of our unissued Series A Convertible preferred stock (“Preferred Stock”), subject to achievement of certain milestones. Each share of Preferred Stock is convertible into <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20251101__20251130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_zTJOFQXfZ1se">1,000 shares of the Company’s Common Stock and votes with the Common Stock on an as converted basis. In January 2026, the Company entered into another restricted stock agreement (the “RSA-2”) with Dr. Trieu, to provide incentive compensation for his extra-ordinary efforts and time to raise capital and successful achievement of certain milestones. The restricted stock agreement provides for a grant of up to <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260101__20260131__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2Q5l9KnyTfh">26,512 shares of our Preferred Stock, subject to achievement of certain milestones. Each share of Preferred Stock is convertible into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_zdppikzPy2D3">1,000 shares of the Company’s Common Stock and votes with the Common Stock on an as converted basis. As of December 31, 2025, Dr. Trieu had earned 12,196 shares of Preferred Stock. As of June 30, 2026, Dr. Trieu earned an additional 8,131 shares of Preferred Stock. As of January 1, 2025, approximately $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20250101__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_zTihxvED2xgh" title="Short term loan">2 million was outstanding and payable to Autotelic. During the year ended December 31, 2025, Autotelic Inc. provided additional short-term funding of approximately $1.0 million to the Company. During the six months ended June 30, 2026, Autotelic Inc. provided additional short-term funding of approximately $75,000 to the Company. As such, approximately $<span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20260630__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_zPtKLBPW1U9a" title="Short term loan">3.1 million was outstanding and payable to Autotelic at June 30, 2026. Contingent shares issuable to Autotelic The Company is contingently obligated to issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NASDAQ. No cash was paid for the Asset Transfer Agreement. For more information, refer to Note 9 – Lunai Bioworks Transactions: Asset Transfer Agreement and Note 15 – Commitment and Contingencies: Autotelic Asset Transfer Consideration. Artius Consulting Agreement In March 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. King is the Managing Member, entered into an amendment to the Consulting Agreement dated December 1, 2018, under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time. For more information on this Agreement, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. <span id="xdx_903_eus-gaap--OperatingCostsAndExpenses_do_c20260401__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember_zZrtvQvLDaA4" title="Related party expenses"><span id="xdx_909_eus-gaap--OperatingCostsAndExpenses_do_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember_zUzO6E5CfRVh" title="Related party expenses"><span id="xdx_900_eus-gaap--OperatingCostsAndExpenses_do_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember_zPPL1mzv8tif" title="Related party expenses"><span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_do_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember_z3GSCArsBTf6" title="Related party expenses">No expense was recorded during the three or six months ended June 30, 2026 and 2025 related to this Agreement. Mosaic ImmunoEngineering, Inc. In April 2024, the Company entered into a Term Sheet with Mosaic. For more information on the Term Sheet, refer to Note 1 of this Quarterly Report. Steven King, our Board member, is the CEO of Mosaic. The Company had advanced $<span id="xdx_90C_eus-gaap--ProceedsFromOtherDebt_pn3n3_c20240401__20240430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenKingMember__us-gaap--TypeOfArrangementAxis__custom--TermSheetAgreementMember_zjgLFKvcoyR8" title="Term sheet payment advanced">40 thousand to Mosaic in accordance with the terms of the Term Sheet, and Mosaic has repaid the amount, with interest to the Company as of December 31, 2024. In addition, the Company, on behalf of our JV, had entered into an agreement with Mosaic to provide consulting services related to CMC activities for the JV. The expenses for these services have been paid for by the JV. As such, the Company has not recorded any expenses or accounts payable in this regard during the three months ended June 30, 2026 or 2025, related to this Agreement. Maida Consulting Agreement Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020, under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials. For more information on this Agreement, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. Effective April 1, 2022, Dr. Maida’s compensation has been borne by the JV. No expense was recorded during the three and six months ended June 30, 2026, and 2025 related to this Agreement.

500

1000

164444

16444

148000

250000

35000

50000

125000

175000

24387516

1000

26512

1000

12196

8131

1000000.0

75000

3100000

40000

NOTE 11 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (MAST HILL) In August of 2025, the Company entered into an Equity Purchase Agreement (“EPA”) and Registration Rights Agreement with Mast Hill. Under the terms of the EPA, the Company issued warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250831__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zimivlG7mEl1" title="Warrants issued to purchase common stock">3,350,000 shares of Common Stock to Mast Hill. Further, under the terms of the EPA, Mast Hill agreed to purchase from the Company up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250801__20250831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zxxm03Ft2Iye" title="Value of shares available for purchase">25,000,000 of the Company’s Common stock upon effectiveness of a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission and subject to certain limitations and conditions set forth in the Equity Purchase Agreement. The Registration Rights Agreement provided that the Company would (i) file the Registration Statement with the SEC by October 1, 2025: and (ii) use its best efforts to have the Registration Statement declared effective by the Commission at the earliest possible date (in any event, within 90 after days after the execution date of the definitive agreements). The Company filed the initial Form S-1 with the SEC on November 21, 2025 and the SEC declared the S-1 effective on December 23, 2025. The Company filed a prospectus on Form 424B3 with the SEC on December 23, 2025. Following effectiveness of the Registration Statement, and subject to certain limitations and conditions set forth in the Equity Purchase Agreement, the Company shall have the discretion to deliver put notices to the Investor and the Investor will be obligated to purchase shares of the Company’s Common Stock based on the investment amount specified in each put notice. <span id="xdx_90D_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250801__20250831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zVSndwK4uT38" title="Share puchase description">The minimum amount that the Company shall be entitled to put to the Investor in each put notice is $5,000 and the maximum amount is up to the lesser of $0.5 million or twenty percent (20%) of the average daily trading value of the Company’s Common stock. Pursuant to the Equity Purchase Agreement, the Investor will not be permitted to purchase, and the Company may not put shares of the Company’s Common Stock to the Investor that would result in the Investor’s beneficial ownership of the Company’s outstanding Common Stock exceeding 4.99%. The price of each put share shall be equal to ninety seven percent (97%) of the market price, which is defined as the lesser of (i) closing bid price of the Common stock on the trading date immediately preceding the respective put date, or (ii) the lowest closing bid price of the Common Stock during the seven (7) trading days immediately following the clearing date associated with the applicable put notice. In connection with the EPA, the Company issued <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250831__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lHypxUjX6i" title="Warrants issued to purchase common stock">3,350,000 warrants to Mast Hill and recorded a fair value deferred finance cost of approximately $122,000. During the three months ended June 30, 2026, the Company sold a total of 137,987 shares of Common Stock at $0.04 for total gross proceeds of $6,630, and incurred issuance costs of approximately $1,500.

3350000

25000000

The minimum amount that the Company shall be entitled to put to the Investor in each put notice is $5,000 and the maximum amount is up to the lesser of $0.5 million or twenty percent (20%) of the average daily trading value of the Company’s Common stock. Pursuant to the Equity Purchase Agreement, the Investor will not be permitted to purchase, and the Company may not put shares of the Company’s Common Stock to the Investor that would result in the Investor’s beneficial ownership of the Company’s outstanding Common Stock exceeding 4.99%. The price of each put share shall be equal to ninety seven percent (97%) of the market price, which is defined as the lesser of (i) closing bid price of the Common stock on the trading date immediately preceding the respective put date, or (ii) the lowest closing bid price of the Common Stock during the seven (7) trading days immediately following the clearing date associated with the applicable put notice.

3350000

122000

137987

0.04

6630

1500

NOTE 12 - STOCKHOLDERS’ EQUITY The following transactions affected the Company’s Stockholders’ Equity: Issuance of Common Stock during the six months ended June 30, 2026 In January 2026, the Company issued 1,600,446 of the Company’s Common Stock as commitment shares to Mast Hill in connection with a Note purchase agreement. In April 2026, the Company issued 300,000 shares to Fourth Man in exchange for one time waiver of their right to adjustment of conversion price of their March 2022 note. In May 2026, the Company sold 137,987 registered shares of Common Stock at $0.04 to Mast Hill in connection with EPA. In June 2026, the Company issued 11,877,507 shares of Common Stock to Mast Hill in connection with the note conversion of their May 2022 Note. In June 2026, the Company issued 500,000 shares of Common Stock to Pacific Pier in connection with the new Pacific Pier Note. Issuance of Common Stock during the six months ended June 30, 2025 In March 2025, Fourth Man partially converted approximately $68,000 of their debt, including accrued interest plus $1,750 for legal fees. In connection with the partial Note conversion, the Company issued 1,002,832 shares of Common Stock to Fourth Man.

1600446

300000

137987

0.04

11877507

500000

68000

1750

1002832

NOTE 13 – PREFERRED STOCK The Company has authorized 15,000,000 shares of Convertible Preferred Stock, par value $0.01 per share, of which, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zckx6DTy0fb6" title="Preferred stock, shares authorized">5,000,000 shares have been designated as Series A Convertible Preferred Stock (the “Preferred Stock”). In November 2025, the Company entered into RSA-1 with Dr. Vuong Trieu, our CEO, and granted him <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pp3d_c20251101__20251130__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zzu7HbsnB1zk" title="Restricted stock grant">24,388 shares of our Preferred Stock, which were subject to a vesting schedule upon achievement of certain corporate milestones and subject to forfeiture if any or all the milestones were not achieved. As of December 31, 2025, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pp3d_c20250101__20251231__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zS99an4DRoqg" title="Restricted stock grant">24,388 shares of the Company’s Preferred Stock were issued to Dr. Trieu, but Dr. Trieu would earn the Preferred Shares as and when he achieved certain milestones. As of December 31, 2025, Dr. Trieu had earned 12,196 shares of Preferred Stock. As of June 30, 2026, Dr. Trieu earned an additional 8,131 shares of Preferred Stock. Each share of Preferred Stock is convertible into 1,000 shares of the Company’s Common Stock, and votes with the Common Stock on an as converted basis. In January 2026, the Company entered into RSA-2 with Dr. Trieu, to provide incentive compensation for his extraordinary efforts and time to raise capital and successful achievement of certain milestones. The restricted stock agreement provides for a grant of up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260101__20260131__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwfOdlk16VGg">26,512 shares of our Preferred Stock, subject to achievement of certain milestones. Each share of Preferred Stock is convertible into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_z3M7fI2wS4r6" title="Conversion of stock, shares converted">1,000 shares of the Company’s Common Stock upon conversion and votes with the Common Stock on an as converted basis. Dr. Trieu achieved the first milestone and earned <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_z4J7xgp4vdQ5" title="Trading preferred stock shares">4,426 shares of Preferred Stock. SCHEDULE OF PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYNbvfzhT987" style="width: 16%; text-align: right" title="Balance, shares">24,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6CDo70R7s93" style="width: 16%; text-align: right" title="Balance">244</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Issuance of preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zexiDiI0AQm5" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of preferred stock, shares">26,512</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwKBO1rR4Jz2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of preferred stock">265</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6JwetZhyTp7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance, shares">50,900</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zH5oGPUQVEkc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance">509</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfU5xZqUN0d3" style="text-align: right" title="Balance, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zx7diU5oWY3f" style="text-align: right" title="Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Issuance of preferred stock</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zO59p3m6Op4k" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance of preferred stock, shares">24,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhFDrcuR5Plg" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance of preferred stock">244</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zsneoji60bZ7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance, shares">24,388</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zj9CDitnXAr6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance">244</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> For the January 2026 grant, The Company calculated the grant date fair value of the Preferred Stock for the RSA issued to Dr. Trieu as approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20260101__20260630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zw6IDilmVIYg" title="Grant date fair value">2.1 million, recorded stock-based compensation of approximately $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20260401__20260630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zFFHQKw8zmFd" title="Stock based compensation">0.5 and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20260101__20260630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_z5VDp5hlB7v8" title="Stock based compensation">1.2 million for the three months and six mended June 30, 2026 and had approximately $<span id="xdx_90C_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn5n6_c20260401__20260630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zYONfgC0xncg" title="Unamortized expense"><span id="xdx_90D_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn5n6_c20260101__20260630__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_z3uyKD5LmA73" title="Unamortized expense">0.9 million of unamortized expense to be recognized in future periods as and when the milestones are achieved. The Company calculated the grant date fair value of the Preferred Stock for the RSA issued to Dr. Trieu in 2025 as approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zezw1Fp8etR3" title="Grant date fair value">1.6 million, recorded stock-based compensation of approximately $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zgw2gJ6pcggi" title="Stock based compensation">1.1 million during the year ended December 31, 2025 and had approximately $<span id="xdx_90B_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zqGjepNwGbee" title="Unamortized expense">0.5 million of unamortized expense to be recognized in future periods as and when the milestones are achieved. During the three and six months ended June 30, 2026, the Company recorded stock-based compensation of approximately $0.1 million and $0.2 million, respectively, and had approximately $0.1 million of unamortized expense to be recognized in future periods as and when the milestones are achieved.

15000000

0.01

5000000

24388

12196

8131

1000

26512

1000

4426

SCHEDULE OF PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYNbvfzhT987" style="width: 16%; text-align: right" title="Balance, shares">24,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6CDo70R7s93" style="width: 16%; text-align: right" title="Balance">244</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Issuance of preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zexiDiI0AQm5" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of preferred stock, shares">26,512</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwKBO1rR4Jz2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of preferred stock">265</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6JwetZhyTp7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance, shares">50,900</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zH5oGPUQVEkc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance">509</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfU5xZqUN0d3" style="text-align: right" title="Balance, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zx7diU5oWY3f" style="text-align: right" title="Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Issuance of preferred stock</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zO59p3m6Op4k" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance of preferred stock, shares">24,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhFDrcuR5Plg" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance of preferred stock">244</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zsneoji60bZ7" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance, shares">24,388</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zj9CDitnXAr6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance">244</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

24388

244

26512

265

50900

509

24388

244

24388

244

2100000

500000

1200000

900000 900000

1600000

1100000

500000

100000

200000

100000

NOTE 14 – STOCK-BASED COMPENSATION Compensation for services In August 2025, the Company issued 20,322,930 shares of Common stock as service fees of approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20250801__20250831__dei--LegalEntityAxis__custom--JeffersonCapitalMember_zEAjeAd2JRce" title="Compensation for services, amount">1.2 million, as the grant date fair value of the Common Shares to Jefferson Capital, as part of the independent contractor agreement. Jefferson is due to earn certain shares out of the shares issued based on certain milestones, as described in Note 1 to this Report. The Company recognized approximately $0.1 million and $0.2 million as stock-based compensation during the three and six months ended June 30, 2026, and had approximately $0.1 million unamortized expense to be recognized in future periods as and when the milestones are achieved. The Company recognized approximately $1.0 million as stock-based expense during the year ended December 31, 2025 and had approximately $0.20 million unamortized expense to be recognized in future periods as and when the milestones are achieved. In August 2025, the Company issued 4,064,586 shares of Common stock as service fee of approximately $0.2 million to Valor Nation as part of the independent contractor agreement, as the grant date fair value of the Common Shares to Valor Nation. Valor Nation is due to earn the shares issued based over the service period of the agreement. The Company recognized approximately $0.2 million as stock-based expense during the year ended December 31, 2025, and had approximately $0 unamortized expense to be recognized over the remainder of the period of the services. In December 2025, the Company issued 1,818,182 shares of Common stock as service fee of approximately $0.2 million to Outside the Box Capital, Inc. as part of the service agreement, as the grant date fair value of the Common Shares to Outside the Box Capital Inc. Outside the Box Capital Inc. is due to earn the shares issued based over the service period of the Agreement. The Company recognized approximately $0.1 million as stock-based compensation during the three and six months ended June 30, 2026, and had $<span id="xdx_909_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn6n6_c20260401__20260630__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zmFhNb0VAB6b" title="Unamortized expense"><span id="xdx_902_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn6n6_c20260101__20260630__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zFB3ud18XS65" title="Unamortized expense">0 unamortized expense. The Company recognized approximately $62,000 as stock-based expense during the year ended December 31, 2025, and had approximately $<span id="xdx_90F_ecustom--EmployeeServiceShareBasedCompensationUnamortizedCompensationCost_pn4n6_c20250101__20251231__dei--LegalEntityAxis__custom--BoxCapitalIncMember_zc4GMPb2ubf8" title="Unamortized expense">0.14 million unamortized expense to be recognized over the remainder of the period of the services. Options Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The information below details the Company’s associated option activity pre and post-merger. As of June 30, 2026, the Company had options to purchase Common Stock that were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). No further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms. Under the 2017 Plan, up to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zH9XMjLYdacg" title="Number of common stock issued to awards">2,000,000 shares of the Company’s Common Stock may be issued to directors, officers, employees or consultants pursuant to awards granted in the form of non-qualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember_zoM6uwClJRv9" title="Number of common stock authorized for issuance">27,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards, and other stock-based awards. <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9O7nIH3ztd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company’ stock option activity for both qualified and unqualified stock options, is summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the six months ended June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630_zKZBZUPCBiib" style="width: 16%; text-align: right" title="Options outstanding, Balance">23,802,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zuw1ZGU01wkh" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20260101__20260630_zuMSa8bmXyDl" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zHJGEqlkCF7e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630_zhsrZqrYANB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">23,302,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zUQCTc8HKLM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630_zIhjZuSqCQkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,110,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260630_zoO4IfI6n8tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zuwV6wfGWe54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at June 30, 2026: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise prices</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life (In Years) </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 25%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5TlGJPk8mE7" title="Exercise prices, Lower limit">0.10 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zWqHWNxhubJc" title="Exercise prices, Upper limit">0.15</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_znDbpzkguThk" style="width: 16%; text-align: right" title="Number of Outstanding Options">16,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyNvGOkhEsba" title="Weighted Average Remaining Life In Years">5.9</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGgUvMYyqoAk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price"> 0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpUZGmSjVEce" style="width: 16%; text-align: right" title="Number of Exercisable Options">6,057,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zO1rPMV2MKA" title="Exercise prices, Lower limit">0.16 to $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zer5zyKej8Ri" title="Exercise prices, Upper limit">0.21 </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGFeWtzJrn7c" style="text-align: right" title="Number of Outstanding Options">5,502,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaBFz1faw8U7" title="Weighted Average Remaining Life In Years">5.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z0COYsBZbtF4" style="text-align: right" title="Weighted-Average Exercise Price">0.16</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zDWpRPszIKek" style="text-align: right" title="Number Exercisable">5,502,761</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUMCWCTZ5yPj" title="Exercise prices, Lower limit">0.22 to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQTjhf6xBVle" title="Exercise prices, Upper limit">0.37 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuTSaOCdQVuk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">1,550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0ceKRSFcev8" title="Weighted Average Remaining Life In Years">1.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUeiNDEp5NT7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">0.28</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwdqiw0hgwG8" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">1,550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630_z4WeA8VNt2F8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">23,302,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zmj3nKtdkLU4" title="Weighted Average Remaining Life In Years">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630_zfKI3sabTiDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630_zOm2p05NzX0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">13,110,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The compensation expense attributed to the issuance of the options is recognized as they vest. The employee stock option plan stock options are generally exercisable for <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dc_c20260101__20260630_zUhcXofZbhz2" title="Options exercisable period">ten years from the grant date and vest over various terms from the grant date to three years. As of June 30, 2026, there was no unamortized stock compensation cost related to the stock options granted during the year ended December 31, 2023. Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. The Company amortized $0 stock compensation expense during the three and six months ended June 30, 2026 and 2025 on the 2021 and 2022 grants. For more information on the stock options, refer to 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. Warrants The Company has issued warrants in connection with the various financings conducted by the Company. For more information on the warrant issuances, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. <p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z67QUTBL0Tt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of June 30, 2026 and 2025, respectively are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">For the six months ended June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260630_zyetnbgCvwHd" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">59,415,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zbNsbLci6Lb7" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260630_z40no4simP86" style="text-align: right" title="Number of Stock Options, Issued">1,422,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20260101__20260630_z1T6gHxf6Cr5" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised / cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20260101__20260630_zKZTUZeo8cQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zmQtst3Y6FI3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260630_zoJfiJNV0FYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zxXUjhehNhI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the six months ended June 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_zCJBuimnNOy9" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630_zjxGLEP0pB8e" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zNRGR4uAxWod" style="text-align: right" title="Number of Stock Options, Issued">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20250101__20250630_zu1morpsFEY4" style="text-align: right" title="Weighted-Average Exercise Price, Issued">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised / cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zhrBrlBzANhg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630_zbawYJwV49k3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zEH72SVioDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630_z9nlzxDZPx3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_895_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zGASKp8X5VJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about warrants outstanding and exercisable at June 30, 2026: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life in Years </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN21PloKT8Cg" style="width: 17%; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3hkqCaq0Ie" style="width: 17%; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjwD8JEpjHi">0.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzvDrFm4Aelk" style="width: 16%; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1e4lKlltErg" style="width: 16%; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziUta5WhSGz5" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbsUKyQxchrb" style="text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zMa2RBetaUkg" title="Weighted-Average Remaining Life in Years">0.75-<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSAugRiUrXkk" title="Weighted-Average Remaining Life in Years">0.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNXKj9QDZ7Sc" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8gVEGepLbNf" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxWcTTKtRu65" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zogTmm1RCPEh" style="text-align: right" title="Warrants Outstanding, Number of Warrants">46,555,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRAcVx6UI9jf">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6OKRLsVdmh9" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBkSVlO9Hff" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">46,555,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr5jk3Xej7Hl" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRZf5o6Wt3he" style="text-align: right" title="Warrants Outstanding, Number of Warrants">2,175,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytVWkEg3Qng" title="Weighted-Average Remaining Life in Years">4.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4pUO8sYtiG" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx00DRra52Ba" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">2,175,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNHXZ8xJMDIj" style="padding-bottom: 1pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ78Bsk4XRUb" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">6,772,613</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf9SlBH5UiT1" title="Weighted-Average Remaining Life in Years">4.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmaV9lFfZa6e" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeXjGgXFdzg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">6,772,613</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630_zzcM9UFCLKJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Number Outstanding">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630_zH0CeJygKpnk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630_zUlYAQEnqXTg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number Exercisable">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

20322930

1200000

100000

200000

100000

1000000.0

200000

4064586

200000

1818182

200000

100000

0 0

62000

140000

2000000

27250000

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9O7nIH3ztd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company’ stock option activity for both qualified and unqualified stock options, is summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the six months ended June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630_zKZBZUPCBiib" style="width: 16%; text-align: right" title="Options outstanding, Balance">23,802,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zuw1ZGU01wkh" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20260101__20260630_zuMSa8bmXyDl" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(500,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zHJGEqlkCF7e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630_zhsrZqrYANB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">23,302,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zUQCTc8HKLM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630_zIhjZuSqCQkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,110,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260630_zoO4IfI6n8tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

23802761

0.15

500000

23302761

0.14

13110261

0.16

<p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zuwV6wfGWe54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at June 30, 2026: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise prices</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life (In Years) </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 25%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5TlGJPk8mE7" title="Exercise prices, Lower limit">0.10 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zWqHWNxhubJc" title="Exercise prices, Upper limit">0.15</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_znDbpzkguThk" style="width: 16%; text-align: right" title="Number of Outstanding Options">16,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyNvGOkhEsba" title="Weighted Average Remaining Life In Years">5.9</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGgUvMYyqoAk" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price"> 0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpUZGmSjVEce" style="width: 16%; text-align: right" title="Number of Exercisable Options">6,057,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zO1rPMV2MKA" title="Exercise prices, Lower limit">0.16 to $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zer5zyKej8Ri" title="Exercise prices, Upper limit">0.21 </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGFeWtzJrn7c" style="text-align: right" title="Number of Outstanding Options">5,502,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaBFz1faw8U7" title="Weighted Average Remaining Life In Years">5.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z0COYsBZbtF4" style="text-align: right" title="Weighted-Average Exercise Price">0.16</td><td style="text-align: left"> </td><td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zDWpRPszIKek" style="text-align: right" title="Number Exercisable">5,502,761</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUMCWCTZ5yPj" title="Exercise prices, Lower limit">0.22 to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQTjhf6xBVle" title="Exercise prices, Upper limit">0.37 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuTSaOCdQVuk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">1,550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0ceKRSFcev8" title="Weighted Average Remaining Life In Years">1.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUeiNDEp5NT7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">0.28</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwdqiw0hgwG8" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">1,550,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20260630_z4WeA8VNt2F8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">23,302,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zmj3nKtdkLU4" title="Weighted Average Remaining Life In Years">5.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260630_zfKI3sabTiDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20260630_zOm2p05NzX0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">13,110,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.10

0.15

16250000

P5Y10M24D

0.12

6057500

0.16

0.21

5502761

P5Y2M12D

0.16

5502761

0.22

0.37

1550000

P1Y7M6D

0.28

1550000

23302761

P5Y6M

0.14

13110261

P10Y

P3Y

Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements.

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z67QUTBL0Tt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of June 30, 2026 and 2025, respectively are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">For the six months ended June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260630_zyetnbgCvwHd" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">59,415,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zbNsbLci6Lb7" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260630_z40no4simP86" style="text-align: right" title="Number of Stock Options, Issued">1,422,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20260101__20260630_z1T6gHxf6Cr5" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised / cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20260101__20260630_zKZTUZeo8cQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zmQtst3Y6FI3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260630_zoJfiJNV0FYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zxXUjhehNhI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the six months ended June 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_zCJBuimnNOy9" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630_zjxGLEP0pB8e" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zNRGR4uAxWod" style="text-align: right" title="Number of Stock Options, Issued">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20250101__20250630_zu1morpsFEY4" style="text-align: right" title="Weighted-Average Exercise Price, Issued">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised / cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zhrBrlBzANhg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630_zbawYJwV49k3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zEH72SVioDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630_z9nlzxDZPx3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

59415289

0.13

1422613

0.15

60837902

0.13

31890289

0.13

31890289

0.13 <p id="xdx_895_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zGASKp8X5VJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about warrants outstanding and exercisable at June 30, 2026: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life in Years </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN21PloKT8Cg" style="width: 17%; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3hkqCaq0Ie" style="width: 17%; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjwD8JEpjHi">0.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzvDrFm4Aelk" style="width: 16%; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1e4lKlltErg" style="width: 16%; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziUta5WhSGz5" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbsUKyQxchrb" style="text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zMa2RBetaUkg" title="Weighted-Average Remaining Life in Years">0.75-<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSAugRiUrXkk" title="Weighted-Average Remaining Life in Years">0.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNXKj9QDZ7Sc" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8gVEGepLbNf" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxWcTTKtRu65" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zogTmm1RCPEh" style="text-align: right" title="Warrants Outstanding, Number of Warrants">46,555,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRAcVx6UI9jf">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6OKRLsVdmh9" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBkSVlO9Hff" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">46,555,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr5jk3Xej7Hl" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRZf5o6Wt3he" style="text-align: right" title="Warrants Outstanding, Number of Warrants">2,175,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zytVWkEg3Qng" title="Weighted-Average Remaining Life in Years">4.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4pUO8sYtiG" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx00DRra52Ba" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">2,175,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNHXZ8xJMDIj" style="padding-bottom: 1pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ78Bsk4XRUb" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">6,772,613</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf9SlBH5UiT1" title="Weighted-Average Remaining Life in Years">4.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmaV9lFfZa6e" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeXjGgXFdzg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">6,772,613</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630_zzcM9UFCLKJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Number Outstanding">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20260630_zH0CeJygKpnk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260630_zUlYAQEnqXTg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number Exercisable">60,837,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.13

961539

P0Y4M24D

0.13

961539

0.20

4373750

P0Y9M

P0Y11M23D

0.20

4373750

0.12

46555000

P1Y6M

0.12

46555000

0.12

2175000

P4Y6M3D

0.12

2175000

0.15

6772613

P4Y3M

0.15

6772613

60837902

P1Y10M9D

0.13

60837902

NOTE 15– COMMITMENTS AND CONTINGENCIES Leases Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations. PointR Merger Consideration The total purchase price in the PointR Merger of $<span id="xdx_90B_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PointRMergerMember_zKijyAPke3z8" title="Purchase price">17,831,427 included $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20260630__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PointRMergerMember_zD2JIsTazYt6" title="Contingent consideration of shares issuable">2,625,000 of contingent consideration of shares issuable to PointR shareholders, upon achievement of certain milestones. For more information on the PointR Merger Contingent Consideration, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. Autotelic Asset Transfer Consideration As noted in Note 9 – Lunai Bioworks Transactions, Oncotelic Inc. on behalf of the Company, and Autotelic entered into the Asset Transfer Agreement, pursuant to which Autotelic agreed to transfer all the rights, title and interest to certain Assets In consideration for the transfer of the Assets, the Company shall issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NYSE/NASDAQ. Such shares of the Company have not been issued to Autotelic as of the date of this filing and are not due to be issued till the uplisting of the Company’s stock onto a nationally recognized stock exchange. If the uplisting does not occur, then the shares would not be issuable and neither would the transaction with Lunai be invalidated. For more information, refer to Note 9 – Lunai Bioworks Transactions. Other claims From time to time, the Company may become involved in in legal proceedings, claims and regulatory matters arising in the ordinary course of business. Such matters are subject to uncertainties, and outcomes are not predictable with assurance. As of June 30, 2026, the Company was not a party to any legal proceedings, and management is not aware of any pending or threatened claims or contingencies that, individually or in the aggregate, are probable of resulting in a material loss to the Company’s unaudited condensed consolidated financial statements. Accordingly, no accrual for loss contingencies has been recorded as of June 30, 2026.

17831427

2625000

NOTE 16 – SUBSEQUENT EVENTS Grant of RSU to directors, officers and to certain employees and advisors On July 10, 2026, the board of directors (the “Board”) of the Company approved the granting of certain restricted stock units (“RSUs”) to the Company’s directors and officers; and to certain employees and advisors, that are employed by the Company or affiliates of the Company, pursuant to the terms of Restricted Stock Unit Award Agreements (the “RSU Agreements”). In the aggregate <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260710__20260710__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zttZJAKatic5" title="Restricted stock unit award">17,796 RSUs were awarded, including the RSUs issued to the Company’s directors and officers. Each RSU represents the contingent right to receive one (1) share of the Company’s Preferred Stock, subject to performance and time-based vesting. Each share of Preferred Stock is convertible, by its terms, into 1,000 shares of the Common Stock. The RSUs will vest if the Company’s Common Stock is uplisted onto a national stock exchange on or before June 30, 2027, or such period as extended by the Board, subject to the recipient’s continuing to remain in service with the Company or its affiliated entity for a period six months after such uplisting. Each RSU will be settled by delivery of Preferred Stock immediately upon vesting. If the uplisting does not occur by June 30, 2027, or such period as extended by the Board, or, the recipient’s continuous service terminates before six months following the uplisting, then the RSUs would expire and automatically be forfeited. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_zrDxVHyXJy2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The names of the directors and officers who received RSU awards, their titles, and the number of RSUs granted are reflected in the table below: SCHEDULE OF RSU AWARDS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 30%; vertical-align: bottom">Name of the person</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 46%; vertical-align: bottom">Director or Officer</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 20%; vertical-align: bottom">Number of RSUs granted</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Vuong Trieu, Ph.D.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director, Chairman of the Board and Chief Executive Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--VuongTrieuPhDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTttmezIFSP4" title="Director, Chairman of the Board and Chief Executive Officer">2,000</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Anthony E. Maida III, Ph.D., M.A., M.B.A.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director and Chief Medical Officer – Translation Medicine</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--AnthonyEMaidaIIIPhDMAMBAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7thpxcxrdLl" title="Director and Chief Medical Officer - Translation Medicine">1,500</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Steven W. King</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--StevenWKingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQhFiMUCrPsi" title="Director">250</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Seymour Fein, M.D.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Medical Officer and Chief Regulatory Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--SeymourFeinMDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHVuwpZ2J2N4" title="Chief Medical Officer and Chief Regulatory Officer">250</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Saran Saund</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Business Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--SaranSaundMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRGOgOJaN1h4" title="Chief Business Officer">1,500</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Amit Shah</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--AmitShahMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm3ijtrlEpH1" title="Number of RSUs granted">1,500</td></tr> </table> The RSUs have been granted at no cost to all the recipients and are subject to the terms and conditions of the RSU Agreement between the Company and the recipient. The issuance of the RSUs is exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act. New SPA and Note with Pacific Pier On August 3, 2026, the Company entered into a new SPA with Pacific Pier, whereby the Company issued a new Pacific Pier Note in the aggregate principal amount of $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20260803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SpecialPurchaseAgreementsMember_zYGuXhYPHZh5" title="Convertible note payable">178,410 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Pacific Pier has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.06 or 85% of the lowest traded price of the Common Stock on the Principal Market on any Trading Day during the ten (10) Trading Days prior to the respective Conversion Date. The Company also issued <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20260803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SpecialPurchaseAgreementsMember_zt0pEGBJ8U76" title="Shares issued">500,000 of the Company’s common stock as commitment shares to Pacific Pier. Uplisting of the Company’s Common Stock to Nasdaq The Company filed a listing application for the Company’s Common Stock with Nasdaq on July 28, 2026. The Company has received a request for additional information from Nasdaq and the Company is in the process of responding to the request.

17796

Each RSU represents the contingent right to receive one (1) share of the Company’s Preferred Stock, subject to performance and time-based vesting. Each share of Preferred Stock is convertible, by its terms, into 1,000 shares of the Common Stock

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_zrDxVHyXJy2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The names of the directors and officers who received RSU awards, their titles, and the number of RSUs granted are reflected in the table below: SCHEDULE OF RSU AWARDS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 30%; vertical-align: bottom">Name of the person</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 46%; vertical-align: bottom">Director or Officer</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 20%; vertical-align: bottom">Number of RSUs granted</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Vuong Trieu, Ph.D.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director, Chairman of the Board and Chief Executive Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--VuongTrieuPhDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTttmezIFSP4" title="Director, Chairman of the Board and Chief Executive Officer">2,000</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Anthony E. Maida III, Ph.D., M.A., M.B.A.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director and Chief Medical Officer – Translation Medicine</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--AnthonyEMaidaIIIPhDMAMBAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7thpxcxrdLl" title="Director and Chief Medical Officer - Translation Medicine">1,500</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Steven W. King</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Director</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--StevenWKingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQhFiMUCrPsi" title="Director">250</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Seymour Fein, M.D.</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Medical Officer and Chief Regulatory Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--SeymourFeinMDMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHVuwpZ2J2N4" title="Chief Medical Officer and Chief Regulatory Officer">250</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Saran Saund</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Business Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--SaranSaundMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRGOgOJaN1h4" title="Chief Business Officer">1,500</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Amit Shah</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20260710__20260710__srt--TitleOfIndividualAxis__custom--AmitShahMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm3ijtrlEpH1" title="Number of RSUs granted">1,500</td></tr> </table>

2000

1500

250

1500

the Company entered into a new SPA with Pacific Pier, whereby the Company issued a new Pacific Pier Note in the aggregate principal amount of $178,410 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Pacific Pier has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.06 or 85% of the lowest traded price of the Common Stock on the Principal Market on any Trading Day during the ten (10) Trading Days prior to the respective Conversion Date. The Company also issued 500,000 of the Company’s common stock as commitment shares to Pacific Pier.

178410

500000